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Drug-induced liver injury (DILI) is one of the leading reasons for clinical 
candidate termination during drug discovery and development. Similarly, many drugs 
have received a black-box warning or withdrawn from the market due to DILI. It is 
reported that DILI is the 4th leading cause of liver disease leading to liver failure. It is 
estimated that the DILI has an annual incidence rate of 13.9 ± 2.4 cases per 100,000 
people, translating to about 44,000 liver injury patients in the United States each year. 
Despite tremendous research in the predictive field, liver injury prediction using in vitro 
and in vivo models remains a substantial challenge. In this dissertation, I use the three-
manuscript format to address the literature gap based on the drug's toxicological 
properties and its ability to cause mitochondrial dysfunction. I also evaluated the risk of 
liver injury among patients newly treated with atypical antipsychotics.  
Manuscript 1 combined physicochemical properties and in vitro cytotoxicity 
assays, including mitochondrial dysfunction, to build organ-specific univariate and 
multivariable logistic regression models to derive odds ratios for the prediction of clinical 
hepatotoxicity, nephrotoxicity, and cardiotoxicity for 215 marketed drugs.  The 
multivariable hepatotoxic predictive model showed an odds ratio of 6.2 or 7.5 for 
mitochondrial inhibition or drug plasma Cmax >1 µM for drugs associated with liver 
injury, respectively. The multivariable nephrotoxicity predictive model showed an odds 
ratio of 5.8, 6.4, or 15.9 for drug plasma Cmax >1 µM, mitochondrial inhibition, or 
hydrogen bond acceptor atoms greater than 7 for drugs associated with kidney injury, 
respectively. Conversely, drugs with a total polar surface area ≥75Å were 79% less 
likely to be associated with kidney injury. Based on this study, I found that combining 
in silico physicochemical properties descriptors along with in vitro toxicity assays can 
be used to build predictive toxicity models to select small molecule therapeutics with 
 
 
less potential to cause liver and kidney toxicity. Therefore, I recommend a blended 
approach of utilizing readily calculated physicochemical properties combined with in 
vitro toxicity assessments to select small molecules with less potential for clinical organ 
toxicity for the liver and kidney. 
There is a growing need for characterization of age-differences in the 
susceptibility and frequency of DILI caused by hepatotoxicants according to their ability 
to cause mitochondrial dysfunction. Manuscript 2 investigated the relationship between 
liver injury reports submitted to the Food and Drug Administration Adverse Event 
Reporting System with drugs associated with hepatotoxicity via mitochondrial 
mechanisms compared with non-mitochondrial mechanisms of toxicity. This study 
provides evidence that a higher proportion of reports of severe liver injury adverse 
events among drugs are associated with mitochondrial mechanisms of toxicity 
compared with non-mitochondrial mechanisms of toxicity. Furthermore, I found that 
reports of liver injury were 2.2 times more likely to be associated with older patient age 
than reports involving patients ages under 65 years. This finding agreed with the theory 
that age is a susceptibility factor in liver injury via mitochondrial mechanisms of toxicity. 
The findings from this study align with mitochondrial mechanisms of toxicity being an 
important cause of DILI, and this should be further investigated in real-world studies 
with robust designs. 
Compared to typical antipsychotics, atypical antipsychotics (AAP) medications 
have improved safety profiles and rarely cause liver injury. However, no retrospective 
cohort studies have evaluated AAP's liver injury risk using an administrative database 
in the United States. In manuscript 3, I conducted a retrospective cohort study using 
an administrative claims database to estimate the cumulative incidence rate and 
identify risk factors for liver injury in patients taking AAP medications. Univariate and 
multivariate logistic regression analyses were utilized to identify risk factors associated 
 
 
with liver injury. The study estimated the cumulative incidence rate of liver injury 15.2 
to 25.1 per 1000 persons per year among patients newly treated with AAP medications. 
During the first months of treatment, quetiapine, as compared to aripiprazole, was 
associated with a 22% increased risk of liver injury in patients 75 years and younger. 
Our study suggests that patients receiving quetiapine AAP should be monitored for liver 
enzyme elevations frequently during therapy initiation. Patients with comorbidities 
including alcohol abuse, hypertension, obesity, and hyperlipidemia were also found to 
be at higher risk and these patients should be monitored closely for liver injury.  Further 
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This dissertation is written in the three-manuscript format and formatted based 
on the guideline provided by the University of Rhode Island Graduate School. These 
three manuscripts encompassed important aspects of Drug-induced liver injury: most 
influential descriptors for a predictive model (manuscript I), mitochondrial toxicity 
mechanism risk (manuscript II), and liver injury among patients newly treated with 
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Drug-induced organ injury is a major reason for drug candidate attrition in preclinical 
and clinical drug development.  The liver, kidneys, and heart have been recognized as 
the most common organ systems affected in safety-related attrition or the subject of 
black box warnings, and post-market drug withdrawals.  In silico physicochemical 
property calculations and in vitro assays have been utilized separately in the early 
stages of the drug discovery and development process to predict drug safety.  In this 
study, we combined physicochemical properties and in vitro cytotoxicity assays 
including mitochondrial dysfunction to build organ-specific univariate and multivariable 
logistic regression models to derive odds ratios for the prediction of clinical 
hepatotoxicity, nephrotoxicity, and cardiotoxicity for 215 marketed oral drugs.  The 
multivariable hepatotoxic predictive model showed an odds ratio of 6.2 (95% 
Confidence Interval (CI)-1.7-22.8) or 7.5 (95% CI-3.2-17.8) for mitochondrial inhibition 
or drug plasma Cmax >1 µM for drugs associated with liver injury, respectively.  The 
multivariable nephrotoxicity predictive model showed an odds ratio of 5.8 (95% CI-2.0-
16.9), 6.4 (95% CI-1.1-39.3), or 15.9 (95% CI-2.8-89.0) for drug plasma Cmax >1 µM, 
mitochondrial inhibition, or hydrogen bond acceptor atoms greater than 7 for drugs 
associated with kidney injury, respectively.  Conversely, drugs with a total polar surface 
area ≥75Å were 79% (odds ratio 0.21, 95% CI-0.061-0.74) less likely to be associated 
with kidney injury.  Drugs belonging to the Extended Clearance Classification System 
(ECCS) class 4, where renal secretion is the primary clearance mechanism (low 
permeability drugs that are bases/neutrals), were 4 (95% CI-1.8-9.5) times more likely 
to cause kidney injury with this data set.  Alternatively, ECCS class 2 drugs, where 
hepatic metabolism is the primary clearance (high permeability drugs that are 




kidney injury.  A cardiotoxicity model was poorly defined using any of these drug 
physicochemical attributes.  Combining in silico physicochemical properties descriptors 
along with in vitro toxicity assays can be used to build predictive toxicity models to 
























The high rate of safety-related attrition and the enormous cost of developing 
new drugs have encouraged the pharmaceutical industry to move safety evaluation 
earlier into the drug discovery process when structure-toxicity relationship 
determination is feasible.1  This can be easily done before more expensive toxicity 
testing is conducted in small (rodent) and large (non-rodent) animal species an 
advance of clinical trials that may ultimately be poorly predictive of human drug-
induced organ injury.2-4  Hence, various in silico tools, such as structural alerts, 
physicochemical properties,5-7 and in vitro toxicity assays8, 9 have been proposed to 
accelerate drug development with adequate safety and at a lower cost.  
The association of physicochemical properties with animal and human toxicity 
has been widely accepted and published in the literature.10-14   Hughes et al. 
demonstrated that highly lipophilic, less polar drug candidates are more likely to cause 
safety issues in animal exploratory toxicity studies using 245 small molecules.10  The 
utilization of physicochemical properties combined with general cytotoxicity assays to 
progress potential clinical candidates into animal toxicity studies has been explored.11-
13 For human liver organ toxicity, Leeson (2018) successfully utilized physicochemical 
properties to predict "Most-DILI-" from "No-DILI-"concern drugs in 1841 marketed 
small molecule therapeutic drugs.14 The author demonstrated high value of lipophilicity 
and fraction of carbon atoms that are sp3 hybridized (Fsp3) when combined with 
maximum applied daily dose for separating these binary (categorical) predictions of 
human liver toxicity.14 
There has been utilization of absorption, distribution, metabolism, elimination 
(ADME) drug attributes in the prediction of human DILI as well.15-20  Some researchers 
have analyzed DILI relationships based on the Biopharmaceutics Drug Disposition 




as potential drug-drug interactions (DDI).15-17  As expected, the majority of drugs that 
cause human DILI undergo extensive hepatic metabolism18 and, in the absence of 
knowledge of an applied daily dose, it was suggested that avoiding the development 
of BDDCS class 2 molecules (low solubility, extensive mechanism) could be used to 
prevent clinical DILI.19  Using this approach, Chan et al. stated there was little 
additional value in adding in vitro toxicity assays over the BDDCS classification 
system.20 Similar to BDDCS classification, some researchers have utilized the 
Extended Clearance Classification System (ECCS) for early predictions of rate-
determining clearance mechanisms.21  ECCS has been utilized to understand ADME 
attributes, and enabling victim DDI predictions in chemical design and molecule 
selection.22 
From a biological perspective, several assays related to hepatotoxicity have 
also been used for predictions.23 These involve measurements of cytotoxicity, or 
mitochondrial dysfunction, and/or bile acid efflux inhibition.23  Some studies have 
utilized mitochondrial toxicity assessments alone24 or in combination with other assays 
to highlight drugs of Most-DILI-concern.25  Although, these approaches have been 
useful in highlighting drugs with Most-DILI-concern potential, neither of these later 
approaches considered the value of combining physicochemical properties, or ECCS 
classifications, with relevant in vitro mechanistic assays.    
Aleo et al. recently showed the value of combining major physicochemical 
properties with in vitro assays relevant to liver safety for discriminating DILI compounds 
across and within categories of liver injury (Most-, Less- and No-DILI-concern) along 
with their FDA label for liver safety (no mention, adverse reactions, warnings and 
precautions, black box warnings and withdrawn).26 This hybrid approach offered value 
for new chemical entities in clinical development that were discontinued for significant 




efforts should be made to develop better predictive models of clinical organ toxicity 
beyond the liver.  To our knowledge, there is a significant gap in the literature for 
integrating both physicochemical properties with in vitro mechanistic assays for 
predicting major organ system toxicities beyond the liver, such as kidney and heart. 
Because mitochondrial dysfunction is a universal safety concern across 
multiple organ systems, the utilization of mitochondrial toxicity assays and 
physicochemical properties for the prediction of organ toxicity was explored by Rana 
et al. using 228 drugs.27  It was concluded that testing drugs in mitochondrial assays 
at 100 times the maximum total plasma concentration (Cmax) provided the highest 
sensitivity for predicting hepatotoxicity. Furthermore, in-depth physicochemical 
properties space was explored for the drugs that were positive in the mitochondrial 
assays compared with those that were tested negative.  Drugs testing positive in 
mitochondrial assays possessed different physicochemical properties in terms of 
lipophilicity and were prone to be in either acid or neutral ionization states compared 
with drugs that tested negative.27  In this study, we proposed to expand the concept of 
combining physicochemical properties with in vitro assays to explore the major organ 
system toxicity other than hepatotoxicity.  Furthermore, we expanded the combination 
of the most predictable characteristics of in vitro assays and physicochemical 
properties to build human organ toxicity predictive models using univariate and 
multivariable logistic regression modeling.  We hypothesized that there are different 
sets of in vitro assays, and physicochemical properties can be predictive of toxicity in 
selected organs (liver, kidney, and heart). We examined this relationship quantitatively 
using the odds ratio for the prediction of clinical organ toxicity. 
The overall goal of this study is to help build better predictive models for 
hepatotoxicity, nephrotoxicity, and cardiotoxicity using the least number of input 




savings.  Drug physicochemical properties (hydrogen bond donor and acceptor count, 
Fsp3, calculated log partition coefficient (cLogP), total polar surface area (TPSA), 
molecular weight (MW), and Cmax values), ECCS class, and effects using in vitro 
mechanistic assays (Transformed Human Liver Epithelial (THLE) cytotoxicity assays, 
glucose/galactose assays, and mitochondrial respiration inhibitory/uncoupling assays) 
of 215 pharmaceutical drugs were investigated via utilization of multivariable logistic 























The physicochemical properties, ECCS classes, and in vitro results of the 
marketed drugs were utilized from previously published methods.21, 27-32  The in vitro 
assay results were previously published by Rana et al. or Shah et al.13, 23, 27 
Inclusion criteria for the drugs 
The present study included 215 drugs (70 hepatotoxic drugs, 44 cardiotoxic 
drugs, 45 nephrotoxic drugs, and 56 drugs not known to cause human organ toxicity).  
These drugs were small molecules, represented diverse target pharmacology, and 
belonged to multiple indications and therapeutic areas.  Hepatotoxic drugs and drugs 
not known to have organ toxicity (Most-, Less- and No-DILI-concern) were annotated 
using the United States National Center for Toxicological Research Liver Toxicity 
Knowledge Base (NCTR-LTKB). 33, 34  Nephrotoxic and cardiotoxic drug classification 
were adapted from previously published literatures from Lin and Will, and Rana et al.27, 
30  Lin and Will (2012) classified nephrotoxic and cardiotoxic drugs via automated 
queries from published literature on drug-induced toxicity; this information was curated 
manually.27  All the compounds selected for three categories of organ toxicity were 
reported in the previous publications or had literature evidence of specific organ black 
box warning or withdrawal.13, 23, 27, 30, 35   
To build a separate model for each organ toxicity group using a univariate and 
multivariable logistic regression model, a drug was classified as either positive (1) or 
negative (0) outcome of organ toxicity.36  For drugs where multiple papers reported 
two or more organ toxicities, drug adverse event counts (using FAERS database) were 
utilized to include a drug in one organ toxicity category.  The method of calculating 
drug adverse event counts has been described previously.27, 37 




Medicinal chemists in the pharmaceutical industry have utilized Lipinski’s Rule 
of 5 as the first step to eliminate molecules with poor physicochemical properties for 
oral bioavailability.38  More recently, ECCS computational modeling has been 
employed to facilitate the early assessment of the rate-determining step in drug 
clearance, pharmacokinetic variability, and proposed metabolism/excretion pathway 
based on basic physicochemical properties and passive membrane permeability 
assessments.21, 22   This differs slightly from estimates of BDDCS classification, which 
focuses on the extent of drug elimination and solubility.21 
Physicochemical properties such as TPSA and cLogP are indicative of drug 
polarity and lipophilicity.  Drugs with high lipophilicity and low polarity (cLogP≥3 and 
TPSA<75 Å2) had significantly increased toxic outcomes in animal studies compared 
with drugs that had both lower lipophilicity and higher polarity (cLogP<3 and 
TPSA≥75 Å2).10, 12, 39 Along with higher lipophilicity, lower Fsp3 has been reported with 
predicting drugs with high potential of liver injury.14  MW is essential in demonstrating 
on- and off-target drug toxicity.13  MW greater than 400 Da has been associated with 
toxicity and considered as a less desirable characteristic in an orally administered 
drug.14, 21 A previous study reported that reducing the number of heteroatoms, 
especially hydrogen-bond donors and acceptors, has been used to decrease P-
glycoprotein transporter efflux.40  The hydrogen bond donor (greater than 5) and 
acceptor (greater than 7) counts have been used for optimal drug exposure.39 Finally, 
drugs with higher Cmax have been demonstrated in several studies with a higher risk 
of organ injury.14, 23, 27, 41 
This study utilized Respirometric Screening Technology (RST), a high 
throughput screening mitochondrial assay that has been used to measure effects on 
respiration (inhibition or uncoupling) in isolated rat liver mitochondria along with cellular 




was determined using the previously published glucose/galactose model.28, 31, 42-44  
Furthermore, this study also included a general cytotoxicity assay that measures the 
effect of a compound on Transformed Human Liver Epithelial (THLE) cells viability.  
This assay has been reported for being a valuable tool to select compounds for 
progression into in vivo studies.12, 13  
In the present study, we have used independent variables including 
physicochemical properties (hydrogen bond donor & acceptor count, Fsp3, cLogP, 
TPSA, MW, and Cmax values) and in vitro assay results (THLE cytotoxicity assay, 
glucose/galactose assays, and mitochondrial respiration inhibitory/uncoupling assays) 
to develop predictive models for liver, kidney, and heart organ toxicity.  The study 
further incorporated the ECCS based on clearance, metabolism, permeability, and drug 
ionization states to evaluate their association with the organ toxicity group.   
Dependent variable 
For this study, the dependent variable was whether a drug was associated with 
an increased risk of hepatotoxicity, nephrotoxicity, or cardiotoxicity (yes or no). 
Statistical Analysis 
This study intended to use binary outcome models to build separate predictive 
models for each organ toxicity drug group. There has been evidence in the literature 
for utilizing this approach to develop risk based adjustment models.36  Each toxic drug 
group (hepatotoxic, nephrotoxic, and cardiotoxic) was compared against a no organ 
toxic drug group.  The differences in the continuous variables of drug characteristics 
between the comparison groups were assessed using the Student t-test for 
independent samples.  All  continuous variables were dichotomized using clinically-
relevant criteria available in the literature (as shown in Table 1).  Collinearity among 




indices, and variance proportions.  Highly correlated variables were identified, and the 
less important variables were removed from further inclusion in univariate and 
multivariable logistic regression modeling.   
The study first specified a univariate logistic regression model for each toxicity 
group (against no organ toxic group) and calculated the odds ratios, 95% confidence 
intervals, and p-values.  The p-values less than 0.2 (less stringent with 80% probability 
of association) in the univariate logistic regression models were included for further 
multivariable logistic regression analyses.  Afterward, a stepwise multivariable logistic 
regression model via backward elimination was utilized to choose the most predictive 
variables after removing insignificant variables.  The odds ratios for final fitted models, 
95% confidence intervals, and p-values were calculated in this multivariable logistic 
regression model after removing the insignificant variables with p  ≥ 0.2.  The univariate 
analysis evaluated the unadjusted association between organ toxicity outcome and a 
single variable.  In contrast, the multivariable analysis assessed the adjusted 
association between organ toxicity outcome with several variables simultaneously.45 
The Hosmer and Lemeshow goodness-of-fit test was performed to determine if 
the model fit adequately, where p > 0.05 indicated that the model fit appropriately.45  
The AUC-ROC (Area Under Curve – Receiving Operating Curve) method was used to 
evaluate performances of different predictive models, and to identify the optimized 
model with the most influential predictors of the organ toxic drugs.  AUC-ROC is a plot 
of sensitivity vs. 1-specificity.46  AUC-ROC evaluates the discrimination power of the 
model; an AUC-ROC value close to 1 suggests that selected variables were able to 
separate organ toxic drugs from no organ toxic drugs.  Whereas, an AUC-ROC value 
close to 0.5 indicates that selected variables were not able to separate organ toxic 




(SAS Institute, Cary, NC), and all statistical tests were two-sided with a significance 





















Characteristics of physicochemical properties and in vitro assay results of organ 
toxicity drugs 
The physicochemical properties (hydrogen bond donor and acceptor count, 
Fsp3, cLogP, TPSA, MW, and Cmax values) and in vitro assay results (THLE 
cytotoxicity assay, glucose/galactose assays, and RST mitochondrial respiration 
inhibitory/uncoupling assays) of each organ toxicity drug groups were compared with 
the no organ toxicity group (Table 2).  For hepatotoxic drugs, there was a statistically 
significant (p-value < 0.05) difference for Cmax, THLE cytotoxicity assay, and RST 
mitochondrial inhibitory/uncoupling assays from the no organ toxic drugs. For 
nephrotoxic drugs, there was a statistically significant difference for hydrogen donor & 
acceptor count, TPSA, MW, and Cmax values from the no organ toxic drugs.  For 
cardiotoxic drugs, there was a statistically significant difference for cLogP and  THLE 
cytotoxicity assay from the no organ toxic drugs.   
The collinearity assessment found that the results of both HepG2 glucose and 
HepG2 galactose in vitro assays were highly correlated (via variance inflation factors, 
condition indices, and variance proportions).  These two variables are cell-based 
assays measuring mitochondrial health as cell viability in two different media, glucose, 
and galactose. HepG2 galactose assay along with the ratio of the cytotoxicity results 
allow the detection of drugs causing mitochondrial toxicity in cell- based assays.31, 47  In 
galactose media, HepG2 cells are forced to use mitochondrial oxidative 
phosphorylation (circumventing the Crabtree effect) instead of glycolyis making them 
more prone to drugs causing mitochondrial toxicity.31  Therefore, the results in the 




galactose assay, along with the ratio of the cytotoxicity results for mitochondrial health, 
were used.   
Univariate regression models for hepatotoxic, nephrotoxic, and cardiotoxic 
drugs 
The literature references and the cut-off criteria utilized for physicochemical 
properties and in vitro assays for statistical analyses are shown in Table 1.  The 
univariate logistic regression models were specified after dichotomizing the individual 
variables based on published criteria and their association with toxicities.  Table 3 
includes the odds ratios, confidence intervals, and p-values of the univariate logistic 
regression models for hepatotoxic (A), nephrotoxic (B), and cardiotoxic drugs (C).  In 
the hepatotoxic model, p-values were less than 0.2 for Fsp3, Cmax, THLE cell viability 
assay, glucose/galactose ratio, and RST mitochondrial inhibitory/uncoupling assays.  
In the nephrotoxic model, p-values were less than 0.2 for physicochemical properties 
such as hydrogen donor and acceptor count, clogP, TPSA, MW, Cmax, and RST 
mitochondrial inhibitory assay.  Similarly, for the cardiotoxic model, p-values were less 
than 0.2 for hydrogen donor count, Cmax, THLE cell viability assay, HepG2 
glucose/galactose cytotoxicity ratio, and RST mitochondrial inhibitory assays.  The 
variables that had p-values less than 0.2 in all three drug groups were further included 
in the multivariable regression model.    
Stepwise multivariable regression model (via backward elimination) for 
hepatotoxic, nephrotoxic, and cardiotoxic drugs 
A stepwise regression model via backward elimination was utilized to choose 
the statistically significant predictive variables for each drug toxicity category. All the 
descriptors with p-values less than 0.2 (Fsp3, Cmax, THLE cell viability assay, 




included to build a hepatotoxic multivariable model.  In the multivariable hepatotoxic 
predictive model, Cmax (odds ratio 7.5; 95% CI 3.16-17.79; p < 0.0001), and RST 
mitochondrial inhibitory assay (odds ratio 6.21; 95% CI  1.69-22.79; p = 0.0059) were 
significant predictors (Figure 1A).  
Similarly, hydrogen donor and acceptor count, clogP, TPSA, MW, Cmax, and 
RST mitochondrial inhibitory assay were included to build the nephrotoxic predictive 
model.  In the multivariable nephrotoxic model, hydrogen acceptor (odds ratio 15.94; 
95% CI  2.85-89.00; p = 0.0016), TPSA (odds ratio  0.21; 95% CI  0.061-0.74; p = 0.01), 
Cmax (odds ratio 5.86; 95% CI 2.03-16.9; p = 0.001), and RST mitochondrial inhibitory 
assay (odds ratio 6.43; 95% CI 1.05-39.31; p = 0.043) were the significant predictors 
(Figure 1B).   
Finally, hydrogen donor count, Cmax, THLE cell viability assay, HepG2 
glucose/galactose cytotoxicity ratio, and RST mitochondrial inhibitory assays were 
included to build cardiotoxic predictive model.   In the multivariable cardiotoxic 
predictive model, only the galactose assay (odds ratio 2.77; 95% CI 1.07-7.19; p = 
0.036) indicated a statistically significant prediction of toxicity (Figure 1C).   
Evaluation of predictive model performance via ROC-AUC (Receiving Operating 
Curves – Area Under Curve) and the Hosmer and Lemeshow goodness-of-fit 
tests 
Assessment of the predictive models was conducted using ROC-AUC, as 
shown in Figures 2 (A, B, and C).  Figure 2A shows the ROC-AUC values of all the 
predictors individually, along with the combinations of other statistically significant 




and THLE cytotoxicity assays, the AUC-ROC value was 0.78, indicating a good fit for 
the predictive model.   
Similarly, Figures 2B and 2C show the ROC-AUC values of all the predictors 
individually along with a combination of other statistically significant predictors for 
nephrotoxic and cardiotoxic models, respectively.  As shown in Figure 2B, for the 
nephrotoxic predictive model, based on hydrogen acceptor, TPSA, MW, Cmax, and 
RST mitochondrial inhibition assay, the AUC-ROC value was 0.84, indicating a good 
predictive model.  The cardiotoxic predictive model did not perform as well as 
hepatotoxic and nephrotoxic models, having a ROC-AUC value of 0.65 (as shown in 
Figure 2C).  For the cardiotoxic predictive model, it can be assumed that this model 
can predict the cardiotoxic drug only slightly better than a random classifier. 
The Hosmer and Lemeshow goodness-of-fit tests were performed to determine 
if the model for each drug toxicity group fit adequately.  The three predictive models fit 
appropriately (p = 0.43 for the hepatotoxic model, p = 0.84 for the nephrotoxic model, 
and p  = 0.21 for the cardiotoxic model). 
Utilization of an ECCS to predict organ toxic drugs 
Based on the ECCS, compounds are categorized as Class 1-metabolism as 
mainly systemic clearance mechanism (high permeability acids/zwitterions with MW ≤ 
400 Da), Class 2-where metabolism is primary clearance mechanism (high 
permeability bases/neutrals), Class 3A-renal clearance (low permeability 
acids/zwitterions with MW ≤ 400 Da), Class 3B-transporter mediated hepatic uptake or 
renal clearance (low permeability acids/zwitterions with MW ≥ 400 Da), and Class 4-
renal clearance (low permeability bases/neutrals).  The study reported that none of the 
ECCS classes were associated with hepatotoxic or cardiotoxic drugs (as shown in 




0.0007) and ECCS class 4 (odds ratio 4.1; CI 1.77-9.52; p = 0.001) showed 
discriminatory value for predictions of nephrotoxic drugs from the drugs with no organ 






















1.5 DISCUSSION  
Accurate prediction of safety-related severe adverse effects of drug candidates 
early in the development process is a high priority for pharmaceutical companies.  
There are various stages of drug development; for example, Exploratory Screen 
Development (ESD), Screening Designed Synthesis (SDS), Lead Development (LD), 
Candidate Selection (CS) leading to Candidate Alert Notice (CAN).   It is generally 
believed that utilization of in vitro or in silico derived predictive models at the early 
stages of discovery improves clinical toxicity prediction.  Different pieces of information 
are available at different stages of drug development.  For example, known or 
calculated physicochemical properties information is available at the ESD or SDS 
stage.  In contrast, various in vitro assays (to assess general cytotoxicity, mitochondrial 
dysfunction, or bile salt export pump disruption) are usually performed at the LD stage 
where enough drug product is made for testing after other chemical properties have 
been refined/optimized.  At ESD or SDS stage, where hundreds or thousands of 
compounds need to be screened, high throughput models described in this study are 
utilized due to simplicity and low cost.  In contrast, at lead development or compound 
selection stage where a sufficient amount of material and few compounds are 
nominated for further development, utilization of more expensive human primary or 
more complex 3D spheroid or organ on a chip model (on the microfluidic platform) are 
utilized when warranted. Furthermore, during preliminary exploratory toxicity studies 
(at LD or CS stage) if there is evidence for particular organ toxicity, organ-specific 
physiologically relevant predictive models are utilized to understand the in vivo animal 
toxicity translation to human. Therefore, it is essential to understand the impact of 
different in silico or in vitro assays predictors associated with different organ toxicities 




The liver, kidney, and heart have been recognized as three major organ 
systems that contribute to costly late-stage drug attrition.48 Therefore, there has been 
an increased need to develop various predictive approaches that can identify drug 
safety liabilities for these organs during the drug design and preclinical stages of the 
drug development process.  For example, various predictive models based on the 
physicochemical properties of a drug or its effect on in vitro toxicity assays to predict 
the human hepatotoxicity potential of a drug.14, 24 These reported models have 
limitations as they utilized either physicochemical properties or in vitro assays alone.  
Furthermore, most of the models have been developed to predict only human clinical 
hepatotoxicity.  Although more recent work has shown the value of integrating 
physicochemical properties along with in vitro assays of relevance for predicting 
hepatotoxicity,35 there is a significant gap in the literature for predictive models of 
nephrotoxicity and cardiotoxicity based on combined approaches that integrate 
physicochemical properties with in vitro assay results.   
In this study, multivariable logistic regression models were developed for 
predictions of hepatotoxicity, nephrotoxicity, and cardiotoxicity.  The present study 
used basic physicochemical properties (hydrogen bond donor & acceptor count, Fsp3, 
cLogP, TPSA, MW, and Cmax values), and the in vitro toxicity assay results (THLE 
cytotoxicity assay, glucose/galactose assays, and RST mitochondrial 
inhibitory/uncoupling assays) for 215 pharmaceutical drugs.  These assays represent 
large-scale screening assays in use either generally or on an ‘ad hoc’ basis at the drug 
design and preclinical stages of the drug development process. 
Hepatotoxicity 
Our study concluded that, based on the hepatotoxic predictive model, if a drug 
were to be positive in THLE cell viability assay (IC50 values less than 100 µM) or caused 




of protein) or had clinical Cmax value of greater than 1 µM, it was 2, 6.2 or 7.5 times 
more likely to cause liver injury respectively.  Combining these separate descriptors in 
a single hepatotoxicity model had a ROC-AUC value of 0.78, suggesting that these 
three descriptors were most influential in separating hepatotoxic drugs from drugs with 
no known organ toxicity.  For hepatotoxicity predictions, using this dataset, cytotoxicity, 
mitochondrial inhibition, and clinical Cmax were stronger predictors than the other 
physicochemical properties analyzed.  Systemic exposure, as measured by Cmax, and 
followed by evidence of mitochondrial inhibition, were influential descriptors, but are 
known or testable at different times during the drug development process compared to 
physicochemical properties.  Although cLogP and TPSA values have been used for 
general toxicity prediction by Hughes et al., they provided a poorer model fit with an 
AUC-ROC value of only 0.576 (as shown in figure 2A).10  Leeson reported that low Fsp3 
values needed to be combined with high lipophilicity and applied dose values to be 
useful for predicting “Most DILI’ drugs.14  However, as an individual descriptor, Fsp3 
provided a poorer model fit for this dataset with an AUC-ROC value of only 0.573 (as 
shown in figure 2A) and did not add as much additional value as the combination of 
Cmax, THLE cytotoxicity, and mitochondrial inhibitor descriptors.  Differences between 
these two models may be driven by differences in the analysis approach as optimized 
physicochemical cut-off values for applied dose, cLogP, and Fsp3 values were 
developed and used by Leeson for individual ionization states based on an extremely 
larger dataset compared to our study.14 
We also investigated the use of our in-house ECCS classification system for 
hepatotoxicity prediction.  To our knowledge, this is the first study that attempted to 
use the ECCS class for the prediction of hepatotoxicity.  However, unlike BDDCS 
classification, ECCS classification, based on our dataset, were not able to add value 




determining clearance mechanism, while BDDCS predicts the extent of elimination 
and solubility. Although BDDCS classification appears more useful for understanding 
and categorizing different clearance mechanisms for predictions of hepatotoxicity,15-17 
it may not be practical in drug design and selection to avoid the development of 
BDDCS class 2 drugs, as previously suggested.19  Many drugs in this category offer 
the intended therapeutic benefit with a low incidence of clinical hepatotoxicity issues 
due to low (≤100 mg) applied dose (e.g., montelukast, losartan, telmisartan, nifedipine, 
simvastatin, and pioglitazone). 
Nephrotoxicity 
Based on the nephrotoxicity predictive model, it was concluded that if a drug 
had a clinical Cmax greater than 1 µM or inhibits mitochondrial respiration at IC50 less 
than 100 nmoles/mg of protein, or has hydrogen bond acceptor atoms greater than 7, 
it is 5.8, 6.4 or 15.9, times more likely to cause kidney injury, respectively.  Conversely, 
drugs that had a TPSA ≥75 Å2 and a MW<400 Da, were 79% and 71% less likely to 
cause kidney injury, respectively.  The nephrotoxic model had a ROC-AUC value of 
0.844, indicating that the descriptors were able to separate nephrotoxic drugs from the 
no organ toxic drugs.  Consequently, for the nephrotoxicity prediction, physicochemical 
properties had much higher significance based on odds ratios that were either highly 
correlated with increased (hydrogen bond acceptor ≥ 7) or decreased (TPSA > 75 Å2 
and a MW < 400 Da) correlation to nephrotoxicity compared with clinical Cmax and 
mitochondrial inhibition assays.  This finding is consistent with literature that correlates 
highly toxic compounds with more hydrogen bond acceptor atoms.49-51  It is suggested 
that the compounds with more hydrogen bond acceptor atoms are highly reactive.49  
Drugs with high hydrogen bond acceptor atom may be more reactive at low 
concentrations through interactions with enzymes or cellular receptor 




hydrogen bond acceptor atom with nephrotoxicity. This study found that this 
physicochemical property exceeded clinical Cmax exposure as a predictor in terms of 
the magnitude of its odds ratio.  There have been previous publications that 
demonstrate the association of MW(≥ 400 Da), TPSA (< 75Å2), and Cmax (> 1 µM) 
with toxic drugs.10, 13, 39, 49, 52  Based on our dataset, the TPSA combined with higher 
Cmax values showed the importance of predicting kidney injury.  Out of all the in vitro 
assays used here, only RST mitochondrial inhibition assay showed the importance of 
predicting kidney injury.   However, in our opinion, assessing other in vitro approaches 
may be necessary to better stratify nephrotoxicity risks, given that our first-tier 
cytotoxicity assays are based on liver-derived cell lines (THLE and HepG2).  For better 
predictions of nephrotoxicity, it may be more important to use primary cultures of renal 
cells or 3 dimensional (3D) organoids that would have a correct balance of renal uptake 
and secretion transporters.53  Lin et al. reported that organ-specific toxicity (liver, 
kidney, and heart) was not better predicted using the corresponding organ-derived 
immortalized cell lines.30  Factors such as drug accumulation within specific organ cell 
types, off-target effects, organ-specific drug metabolism, and clearance may need to 
be assessed since these factors have a significant impact on specific organ toxicity.30  
Interestingly, our study concluded that if a drug is in ECCS class 4, where 
metabolism is primarily through renal clearance (low permeability bases and neutrals), 
it was four times more likely to cause kidney injury than other ECCS class drugs.  On 
the other hand, ECCS class 2 drugs were 77% less likely to cause kidney injury.  
Hepatic metabolism is the primary clearance mechanism of ECCS class 2 drugs (high 
permeability bases and neutrals).  Class 4 drugs are more likely to be distributed and 
accumulate within the kidney, making them more likely to damage proximal tubule 
kidney cells.  Again, due to their primary route of clearance, either kidney or liver, 




organ damage.  Our study was successfully able to utilize the ECCS class for 
differentiating nephrotoxic drugs from drugs with no known organ toxicity.   
Cardiotoxicity 
Based on the univariate cardiotoxicity predictive model, it was concluded that if 
a drug is positive in galactose assay (IC50 values less than 100 µM) and has clinical 
Cmax values greater than 1 µM, it was 2.7 and 1.8 times more likely to cause 
cardiotoxicity, respectively.  Similarly, if a drug has hydrogen bond donor atoms less 
than 5, it was 72% less likely to cause heart injury.  The cardiotoxic model had a ROC-
AUC value of 0.65, indicating a less robust model fit compared to the hepatotoxicity 
and nephrotoxicity models, and the cardiotoxic predictive model was less able to 
separate the cardiotoxic drugs from the no organ toxic drugs.  Heart organ injury has 
both functional (conduction) and structural components.  The compounds selected for 
our analysis were a mixture of structural and functional cardiotoxicants.  Clement et al. 
reported the more holistic approach of integrating electrophysiology, contractility, and 
cell movement/beating for functional assessment along with various structural 
assessments for cardiotoxicity.54  This holistic approach may hold increased value for 
predicting cardiotoxic drugs as they are based on more relevant functional parameters 
of cell health and function. 
Important pieces of information become available at different times during the 
drug discovery, design, and development process.  Known or calculated 
physicochemical properties are determined at the drug design stage such that these 
descriptors can be utilized in predictive models of safety.  Likewise, drug effects in 
mechanistic in vitro assays can only be determined when drug product is made.  While 
estimates of applied dose and clinical exposure are made close to candidate 
nomination, these values are validated during Phase 2 clinical studies.   It was 




odds ratio for each organ model and consider when such information would be 
available.  Predictions of hepatotoxicity required information that was available after 
compound design, making a predictive model hard to implement in that space.  Most 
predictive hepatotoxicity models require the use of clinical dose or systemic exposure 
(Cmax) with physicochemical property space predictors to be useful.  In advance of 
this, measurements of mitochondrial inhibition appear to add some value.  Both 
mitochondrial inhibition of oxidative phosphorylation and drug plasma concentration 
(Cmax) were two descriptors that were useful in predicting both liver and kidney toxicity.  
This finding agreed with previous studies by Porceddu et al., who used multiparametric 
mechanistic endpoints of mitochondrial dysfunction combined with drug plasma 
concentration to predict DILI with high sensitivity and high positive predictive values.24  
Of even more significance is the finding that physicochemical properties could be used 
for predictions of nephrotoxicity, with either highly correlative positive (hydrogen bond 
acceptors ≥7, ECCS class 4) or negative (TPSA ≥75 Å2, MW<400 Da, ECCS class 2) 
predictions.  Such descriptive elements could be used in the drug design process for 
compound design and selection, although ECCS class determinations still require drug 
bulk for passive membrane permeability.  None of the drug attributes appeared to help 












This data set utilized drugs where in vitro data results are available, which leads 
to a relatively small number of drugs evaluated in this study.  Additionally, this may 
introduce selection bias since the drugs used in this study may not be random.   A 
small sample size may lead to a large confidence interval in the calculation of the odds 
ratio, and the lack of statistical power may result a type II error.  The whole dataset 
was used to build models, therefore further studies utilizing these models with 
additional data will be required.  Furthermore, due to the small number of drugs utilized 
to build predictive models, the findings may not be generalized to all the drugs.  The 
result of this study should only be applied to the physicochemical properties of the 
drugs evaluated here; the drugs that fall outside of the physicochemical property space 
evaluated here may hold different results. Finally, the result of this study will not be 
relevant to biotherapeutic drugs.   
To employ logistic regression modeling, drugs were only classified as having 
one type of toxicity; many drugs in the dataset have been associated with multiple 
organ toxicities.  Additionally, increased risk or association does not imply causation.  
Further study is necessary to evaluate the predictive nature of these factors using more 
robust methodologies or in vitro/in vivo mechanistic toxicity studies.  Finally, other 
factors beyond physicochemical properties or in vitro assays can cause toxicity in vivo.  
For instance, in vitro assays lack metabolic functions, appropriate receptors and 
transporters, and cellular architecture.  Moreover, drug-accumulation within specific 
organ cell types, off-target effects, organ-specific drug metabolism, and clearance may 
lead to organ toxicity.  Measuring these factors was beyond the scope of this study; 







The physicochemical properties of a drug influence various parameters such as 
absorption, clearance, the volume of distribution, total plasma concentration, and 
dosing frequency.  Measurements of passive membrane permeability along with RST 
mitochondrial inhibition are useful and relatively affordable compared with in vivo 
animal toxicity studies.  Therefore, we recommend a blended approach of utilizing 
readily calculated physicochemical properties combined with in vitro toxicity 
assessments to select molecules with less potential for clinical organ toxicity for the 
liver and kidney.  As suspected, different models are needed for more accurate 
predictions of hepatic and nephrotoxic drugs.  The multivariable analysis showed that 
drug plasma concentration combined with mitochondrial dysfunction assays was most 
useful in the prediction of hepatotoxic drugs.  However, for nephrotoxic drugs, the 
physicochemical properties of the drugs such as TPSA and hydrogen acceptor atoms 
combined with drug plasma concentration, and mitochondrial dysfunction assay were 
most useful.  Mitochondrial dysfunction assay and drug plasma concentration are two 
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1.9 TABLES AND FIGURES 
Table 1.  Literature references and the threshold utilized for the 
physicochemical properties and the in vitro assays for univariate and 
multivariable logistic regression modeling. 
 
 
Physicochemical properties and in vitro assay thresholds 




Toxic (1) Not Toxic (0) 
 
Hydrogen bond donor atoms 
≥ 5 
Hydrogen bond donor atoms < 5 39  
Hydrogen bond acceptor 
atoms ≥ 7 




Fsp3 ≤ 0.28 Fsp3 > 0.28 14  
cLogP ≥ 3 cLogP < 3 10, 12, 13, 27, 52 
TPSA < 75 Å2 TPSA ≥ 75 Å2 10, 12, 13, 27, 52 
MW ≥ 400 Da MW < 400 Da 14, 39 
Cmax > 1 µM Cmax ≤ 1 µM 10, 12, 14, 41, 55 
THLE assay IC50 ≤ 100 µM THLE assay IC50 > 100 µM 13, 27 
Glucose assay IC50 ≤100 µM Glucose assay IC50 > 100 µM 13, 27 
Galactose assay IC50 ≤100 
µM 
Galactose assay IC50 > 100 µM 13, 27 
Glucose/galactose ratio ≥ 2 Glucose/galactose ratio < 2 27  
RST Uncoupling assay IC50 
≤ 100 nmol/mg of protein 
RST Uncoupling assay IC50 > 
100 nmol/mg of protein 
 
27 
RST Inhibitory assay IC50 ≤ 
100 
nmol/mg of protein 
RST Inhibitory assay IC50 > 100 











Table 2.  Characteristics of physicochemical properties and in vitro assay 
results of organ toxicity drugs. 
 










Mean ± SEM 
Hydrogen 
donor count 
1.942 ± 0.20 
5.844 ± 
0.864* 
1.84 ± 0.22 2.785 ± 0.458 
Hydrogen 
acceptor count 




0.423 ± 0.047 
0.387 ± 
0.0246 
0.40 ± 0.03 
ClogP 2.688± 0.303 0.90 ± 0.71 
3.81 ± 
0.238* 














340.8 ± 23.93 





221.6 ± 16.32 
169.9 ± 
17.63* 
230.2 ± 13.83 
Glucose Assay 237.2 ± 5.44 256.0 ± 12.78 
 209.9± 
17.37 





237.6 ± 14.67 
193.2 ± 
18.52 
229.0 ± 16.04 
RST Inhibitory 
Assay 
223.6 ± 13.8* 264.4 ± 11.52 
263.3 ± 
13.11 






266.5 ± 11.82 
244.5 ± 
14.88 
257.8 ± 11.58 

















Table 3A. Odds of hepatotoxic risk associated with physicochemical properties 
and in vitro assays. 
 












0.58 0.202-1.671 0.3131 
Hydrogen acceptor 
count 
0.926 0.293-2.929 0.8955 
Fsp3 1.933 0.905-4.129 0.0887* 
cLogP 1.24 0.613-2.51 0.5498 
TPSA 0.658 0.324-1.338 0.2479 
MW 1.516 0.681-3.373 0.3078 
Cmax 5.455 2.529-11.76 <0.0001* 
In vitro assays 
THLE cell viability 
assay 
2.302 1.035-5.120 0.0409* 
Galactose assay 1.363 0.564-3.294 0.4916 
Glucose/galactose 
ratio 
6.111 0.729-51.233 0.0952* 
RST inhibitory assay 5.957 1.914-18.536 0.0021* 
RST uncoupling 
assay 
1.875 0.817-4.301 0.1378* 












Table 3B.  Odds of nephrotoxic risk associated with physicochemical 
properties and in vitro assays.  
 












4.177 1.658-10.526 0.0024* 
Hydrogen acceptor 
count 
8.712 3.114-24.377 <0.0001* 
Fsp3 1.66 0.713-3.861 0.2397 
cLogP 0.56 0.246-1.274 0.167* 
TPSA 0.174 0.071-0.430 0.0002* 
MW 3.78 1.611-8.871 0.0023* 
Cmax 4.118 1.784-9.502 0.0009* 
In vitro assays 
THLE cell viability 
assay 
0.917 0.348-2.419 0.861 
Galactose assay 0.708 0.236-2.123 0.5373 
Glucose/galactose 
ratio 
3.929 0.394-39.127 0.243 
RST inhibitory assay 2.811 0.788-10.029 0.1113* 
RST uncoupling 
assay 
0.754 0.266-2.135 0.5944 












Table 3C.  Odds of cardiotoxic risk associated with physicochemical properties 
and in vitro assays. 
 












0.249 0.051-1.217 0.0858* 
Hydrogen acceptor 
count 
0.397 0.0076-2.071 0.2728 
Fsp3 0.607 0.231-1.599 0.3127 
ClogP 1.488 0.673-3.29 0.3263 
TPSA 1.494 0.652-3.419 0.3425 
MW 1.387 0.566-3.401 0.4745 
Cmax 1.731 0.751-3.989 0.1979* 
In vitro assays 
THLE cell viability 
assay 
1.897 0.777-4.628 0.1597* 
Galactose assay 2.629 1.048-6.591 0.0393* 
Glucose/galactose 
ratio 
7.05 0.792-62.733 0.0799* 
RST inhibitory 
assay 
2.459 0.671-9.014 0.1744* 
RST uncoupling 
assay 
1.364 0.528-3.522 0.5217 












Table 4. Comparison of hepatotoxic, cardiotoxic, and nephrotoxic drugs with 
the Extended Clearance Classification System. 
 
Extended Clearance 
Classification System Properties 
























NS 0.0007 NS 




uptake or renal 
clearance 
NS NS NS 
Class4 Renal clearance NS 0.001 NS 












Table 5 Univariate logistic regression model (including odds ratio estimates, 
95% CI, and p-values) for hepatotoxic, nephrotoxic, and cardiotoxic drugs 
using the Extended Clearance Classification System. 
 
 
  Hepatotoxic drugs 
ECCS Class Odds Ratio 95% CI p-value 
Class 1 2.46 0.25-24.35 0.44 
Class 2 0.93 0.46-1.90 0.84 
Class3A >999.9 <0.001->999.9 0.98 
Class3B >999.9 <0.001->999.9 0.99 
Class 4 0.93 0.45-1.92 0.83 
 
  Nephrotoxic drugs 
ECCS Class Odds Ratio 95% CI p-value 
Class 1 <0.001 <0.001->999.9 0.98 
Class 2 0.225 0.095-0.535 0.0007 
Class3A >999.9 <0.001->999.9 0.98 
Class3B <0.001 <0.001->999.9 0.99 
Class 4 4.1 1.77-9.52 0.001 
 
  Cardiotoxic drugs 
ECCS Class Odds Ratio 95% CI p-value 
Class 1 <0.001 <0.001->999.9 0.99 
Class 2 1.66 0.72-3.84 0.23 
Class3A NA* NA* NA* 
Class3B <0.001 <0.001->999.9 0.99 
Class 4 0.70 0.3-1.63 0.41 






Figure 1A: Adjusted odds ratio (including 95% Confidence Interval (CI)) of 




















Multivariable logistic regression model for hepatotoxicity 
prediction
(CI-0.73-5.46; p = 0.18)
(CI-3.16-17.8; p < 0.0001)





Figure 1B: Adjusted odds ratio (including 95% CI) of nephrotoxic risk 



































Figure 1C: Adjusted odds ratio (including 95% CI) of cardiotoxic risk associated 



















Multivariable logistic regression model for cardiotoxicity 
prediction
(CI-1.07-7.19; p = 0.036)
(CI-0.057-1.45; p = 0.13)





Figure 2A: Hepatotoxic model performance evaluation via ROC-AUC, a plot of 











Figure 2B: Nephrotoxic model performance evaluation via ROC-AUC, a plot of 










Figure 2C: Cardiotoxic model performance evaluation via ROC-AUC, a plot of 
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Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and 
post-market drug withdrawals.  Drug-induced mitochondrial toxicity has been shown 
to play an essential role in various forms of DILI, especially in idiosyncratic liver injury. 
This study examined liver injury reports submitted to the Food and Drug Administration 
(FDA) Adverse Event Reporting System (FAERS) for drugs associated with 
hepatotoxicity via mitochondrial mechanisms compared with non-mitochondrial 
mechanisms of toxicity. The frequency of hepatotoxicity was determined at a group 
level and individual drug level. A Reporting Odds Ratio (ROR) was calculated as the 
measure of effect. Between the two DILI groups, reports for DILI involving 
mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42-1.45; p < 0.0001) times 
higher odds compared to drugs associated with non-mitochondrial mechanisms of 
toxicity. Antineoplastic, antiviral, analgesic, antibiotic, and antimycobacterial drugs 
were the top 5 drug classes with the highest ROR values. Although the top 20 drugs 
with the highest ROR values included drugs with both mitochondrial and non-
mitochondrial injury mechanisms, the top 4 drugs (ROR values >18: benzbromarone, 
troglitazone, isoniazid, rifampin) were associated with mitochondrial mechanisms of 
toxicity.  The major demographic influence for DILI risk was also examined.  There was 
a higher mean patient age among reports for drugs that were associated with 
mitochondrial mechanisms of toxicity (56.1 ± 18.33 (SD)) compared to non-
mitochondrial mechanisms (48 ± 19.53 (SD)) (p < 0.0001), suggesting that age may 
play a role in susceptibility to DILI via mitochondrial mechanisms of toxicity.  Univariate 
logistic regression analysis showed that reports of liver injury were 2.2 (odds ratio: 2.2, 
95% CI 2.12-2.26) times more likely to be associated with older patient age, as 




males, female patients were 37% less likely (odds ratio: 0.63, 95% CI 0.61-0.64) to be 
subjects of liver injury reports for drugs associated with mitochondrial toxicity 
mechanisms.  Given the higher proportion of severe liver injury reports among drugs 
associated with mitochondrial mechanisms of toxicity, it is essential to understand if a 
drug causes mitochondrial toxicity during preclinical drug development when drug 
design alternatives, more clinically relevant animal models, and better clinical 
biomarkers may provide a better translation of drug-induced mitochondrial toxicity risk 
assessment from animals to humans.  Our findings from this study align with 
mitochondrial mechanisms of toxicity being an important cause of DILI, and this should 


















Severe drug-induced liver injury (DILI) is a rare, potentially life-threatening 
adverse event with an incidence of 10-15 cases per 10,000 to 100,000 patients per 
year.1-4 The clinical profile of DILI is challenging to diagnose as it can mimic almost any 
type of liver disease 5, 6 and mild, asymptomatic transaminase elevations may mimic 
those caused by diet.7  Prediction of liver injury remains a challenge for the 
pharmaceutical industry, regulators, and clinicians.5  DILI symptoms range from non-
specific mild elevations in liver enzymes (aminotransferases) to severe liver illnesses 
such as cirrhosis or acute hepatitis5, 6  and there is no specific biomarker that links drug 
exposure as the contributing cause of liver injury.8   
There are two types of DILI: intrinsic (i.e., dose-dependent) and idiosyncratic 
(i.e., dose-independent).6  A well-known example of intrinsic DILI is acetaminophen-
induced liver injury, as it is dose-dependent, the onset is hours to days, and 
predictable.9  On the other hand, idiosyncratic DILI is not dose-dependent, occurs in a 
small portion of drug-exposed individuals, its onset is days to weeks, and 
unpredictable.9 Idiosyncratic DILI is highly dependent on environmental and host 
factors that alter the susceptibility of individual patient responses to the drug. Hamilton 
et al. suggested that DILI is the convergence of three influencing risk factors: host 
factors, environmental factors, and drug-specific factors.10  Host-related risk factors 
include genetics, ethnicity, gender, comorbidities, alterations in drug transport, drug 
clearance capabilities, age, and mitochondrial function variability.10  Environmental risk 
factors include lifestyle, viral co-infection, co-prescriptions, diet, and alcohol 
consumption.10  Finally, drug-specific risk factors include the relationship of applied 
dose (exposure) and chemical structure with reactive metabolite formation, 
mitochondrial dysfunction, and lipophilicity.10-12  Therefore, the mechanism of DILI is a 




environmental, and drug-specific factors that influence the liver’s ability to adapt and 
recover from an injury caused by a drug.8 
In recent years, drug-induced mitochondrial toxicity has been shown to play an 
essential role in intrinsic and idiosyncratic DILI. Many medications from different drug 
classes, such as antidiabetic, antilipidemic, antiviral, antibiotic, anti-inflammatory, and 
antipsychotic agents have toxicities mediated by mitochondrial mechanisms, which 
may contribute to DILI.13  Mitochondrial toxicants affect mitochondrial homeostasis by 
numerous mechanisms such as oxidative stress, inhibition or uncoupling of respiratory 
complexes of electron transport chain, impairment of mitochondrial replication or 
promoting mitochondrial DNA damage.14  Drug-induced mitochondrial toxicity is difficult 
to be detected in standard preclinical animal testing models and requires specific 
studies to examine disruptions in liver energy status.15 Only recently, there has been 
the development of clinical biomarkers specific for mitochondrial dysfunction in 
disease16 and DILI17  beyond changes in blood lactate.  With these inadequacies, a 
drug candidate can enter human clinical trials only to fail for evidence of mitochondrial 
toxicity.18, 19  Examples of non-mitochondrial toxicity mechanisms that drive DILI are a 
generation of reactive metabolites, activation of cell death pathways, activation of 
innate or adaptive immune response pathways, or disruption of cellular homeostasis.20  
This study evaluates the frequency of reports of hepatotoxicity injury in drugs that cause 
DILI in mitochondrial mechanisms compared to the non-mitochondrial mechanisms.   
Patient demographics influence risk or susceptibility for DILI.  Boelsterli and Lim 
(2007) indicated that older age and female gender were important susceptibility factors 
for DILI; however, the reasons were still unknown.21  There are no clinical studies that 
link the sensitivity of the female gender to DILI caused by mitochondrial dysfunction.  
Amacher et al. indicated that women are more susceptible to DILI than men.22  Several 




pharmacokinetic or pharmacodynamic differences, interactions of sex hormones with 
signaling molecules, and a difference in immune system responses.22  Similarly, it is 
believed that older adults are more susceptible to DILI caused by mitochondrial 
dysfunction.  The review published by Will et al.13 indicated that the most commonly 
used prescription and over-the-counter (OTC) medications for geriatric patients, such 
as antilipidemic, pain, and heartburn medications, had published reports of toxicities 
linked to mitochondrial dysfunction.13  As the United States’ elderly population is 
growing rapidly, identifying and addressing risk factors of DILI, where mitochondrial 
dysfunction may play a substantial role in adverse events, will be beneficial to this 
vulnerable patient population.  Therefore, in this study, we evaluated the patient age 
and gender associated with DILI reports (measured by reporting odds ratio) for 
hepatotoxicants with mitochondrial and non-mitochondrial injury mechanisms.   
Given that mitochondrial dysfunction is a common characteristic of drugs that 
cause liver injury, a better understanding of the association between the probability of 
liver injury induced by drugs that are mitochondrial toxicants and the influence of 
patient's age and gender would be beneficial for clinicians and drug developers.  If a 
drug is associated with mitochondrial mechanisms of liver injury, clinicians could 
incorporate mitochondrial injury-specific biomarkers into clinical trials.23-25  Additionally, 
the development of clinically relevant animal models or study designs may provide 
drug-induced mitochondrial toxicity risk translation from animals to humans.24  
This study investigated liver injury reports submitted to the Food and Drug 
Administration (FDA) Adverse Event Reporting System (FAERS) and compared the 
frequency of reports between drugs that can cause hepatotoxicity via mitochondrial 
mechanisms and those without mitochondrial mechanisms of toxicity.  Additionally, we 
determined if there were age and gender differences associated with DILI reports 






Data Source:  
The United States Food and Drug Administration (FDA) Adverse Event 
Reporting System (FAERS) database is the largest national repository of spontaneous 
drug event reports, having accumulated over 28 million adverse events reports.  
Healthcare professionals, patients, manufacturers, and lawyers can submit potential 
drug-induced adverse events of small and large therapeutic (biologics) classes and 
medical devices to the FAERS database. The FAERS database has a vital role in post-
market drug surveillance in terms of detection and characterization of drug and device-
related adverse events.   
We extracted adverse event reports from the FAERS database for the 
timeframe from January 1998 to May 2019.  In this study, the reports included severe 
adverse events, such as hospitalization, disability, or death.  The types of reports were 
classified by FAERS as direct, expedited, or periodic.  Direct reports were submitted 
to FDA from consumer or health care professionals; whereas, expedited reports were 
sent from the manufacturer within 15 days of severe adverse events occurrence not 
included in the product label.26  Adverse drug event reports considered periodic were 
submitted from manufacturers, included in the label, and sent to the FDA quarterly or 
annually.26 The main selection criterion was “primary suspect” drugs. “Secondary 
suspect” drugs were excluded because of the greater uncertainty of the association 
between the drug and the reported adverse events.  FAERS reports were coded using 
the MedDRA (Medical Dictionary for Regulatory Activities) terms for DILI.27  Although 




of the FAERS database to investigate emerging DILI adverse events for newly 
marketed drugs.8 
Inclusion/exclusion criteria:  
Drugs that cause liver injury have been annotated using the United States 
National Center for Toxicological Research Liver Toxicity Knowledge Base (NCTR-
LTKB), which utilizes hepatotoxic descriptions from the FDA-approved drug labeling 
regulatory documents as well as evaluating causality evidence in the literature.28  This 
database was created by the FDA to help clinicians, toxicologists, and researchers 
access information on DILI annotation of various drugs. 28, 29 NCTR-LTKB serves as a 
centralized source to study the mechanism of DILI and the development or validation 
of emerging biomarkers and predictive models.29  This is the largest publicly available 
annotated DILI dataset containing three groups based on their potential to cause liver 
toxicity (Most DILI concern-(192 drugs), Lesser DILI concern-(278 drugs), and No-DILI 
concern (312 drugs)) with confirmed causal evidence connecting a drug to liver 
injury.28  The FAERS database uses FDA drug labeling information for the 
classification of drugs according to their potential to cause DILI.  This study utilized 
drugs with "most-DILI concern," which were defined based on hepatotoxicity resulting 
in market withdrawal (in US and ex-US), black box warning, or high severity of liver 
injury noted as part of the warning and precautions label.28-30   Therefore, both 
mitochondrial and non-mitochondrial mechanisms of toxicity groups are associated 
with severe hepatic injury. 
The study drugs represented various drug classes such as analgesic, anti-
inflammatory, antidepressant, antibiotic, antidiabetic, and antineoplastic agents.  Most 
of these drugs had been withdrawn, have boxed warnings, or have warnings and 
precautions for liver injury in their prescribing labels.  The details of DILI severity 




level 1; steatosis, level 2; cholestasis and steatohepatitis, level 3; liver 
aminotransferases increase, level 4; hyperbilirubinemia, level 5; jaundice, level 6; liver 
necrosis, level 7; acute liver failure, and level 8; hepatotoxicity.28  Examples of 
withdrawn drugs include bromfenac, chlorzoxazone, troglitazone, and trovafloxacin, 
which have been assigned a severity level of 8, suggesting evidence of fatal 
hepatotoxicity.  Drugs such as bosentan, danazol, ketoconazole, nefazodone, 
tolcapone, and valproic acid have box warning in their product labeling and have 
severity categories ranging from 3 to 8.   
Classification of Drugs as Mitochondrial Toxicants:  
Drugs with mitochondrial mechanisms of toxicity were defined by literature 
evidence of mitochondrial injury mechanisms (yes or no) of in vitro (e.g., cellular 
production of reactive oxygen species via oxidative stress, inhibition or uncoupling of 
respiratory complexes of electron transport chain, induction of mitochondrial 
membrane permeability transition pore, or mitochondrial DNA damage) or in vivo 
mitochondrial toxicity from animal studies. Our classification was based on the parent 
drug-induced toxicity and not the metabolite.  Possible drug effects on mitochondrial 
biogenesis or respiratory capacity were not considered. Drugs with the non-
mitochondrial mechanisms of toxicity were defined by literature evidence of the 
absence of mitochondrial injury mechanisms or lack of evidence. It is important to note 
that 8.2% of drugs had no literature evidence of the type of toxicity mechanism, 
meaning it could be a mitochondrial or non-mitochondrial mechanism.  Furthermore, 
the non-mitochondrial mechanisms of toxicity drugs are not proven to have non-
mitochondrial mechanisms.  For these drugs, there is simply no evidence of 







We determined the number of reports for hepatotoxicity at a group level and 
an individual drug level using the Reporting Odds Ratio (ROR). As shown in Table 1, 
we calculated total hepatotoxicity and all other adverse events for both the DILI groups.  
For ROR calculations, numerators are derived by multiplying the hepatotoxicity reports 
for mitochondrial mechanisms of toxicity drug group with all other adverse event 
reports of non-mitochondrial mechanisms of toxicity per drug group. The denominator 
is calculated by multiplying hepatotoxicity adverse event reports of non-mitochondrial 
mechanisms of toxicity with all the adverse events reported for mitochondrial 
mechanisms of toxicity per drug group.31  Therefore, the ROR for drugs associated 
with mitochondrial mechanism of toxicity was 1.43 (ROR = (40,343 X 1,342,486) / 
(586,989 X 64,358) = 1.43).   
We also examined the RORs at the individual drug level, as shown in Table 2.  
A case (hepatotoxicity reports) or non-case (all other adverse event reports) 
disproportionality approach was utilized by creating a two-by-two contingency table, 
as demonstrated below using acetaminophen as an example 31  During this timeframe, 
a total of 383,540 hepatotoxicity reports and a total of 27,852,908 adverse event 
counts of any drug type were collected.  For ROR calculations, numerators are derived 
by multiplying the hepatotoxicity reports for a drug of interest with all other adverse 
events reports. The denominator is calculated by multiplying hepatotoxicity adverse 
event reports of all other drugs (excluding acetaminophen) with all the adverse events 
reported with a drug of interest31 (ROR for Acetaminophen = (8,509 X 27,852,908) / 
(51,732 X 383,540) = 11.94).  Within the timeframe, a ROR higher than 1 for a drug 
indicates a higher proportion of severe liver injury reports for a drug of interest than all 




with proportionally more reports for serious liver adverse events than other drugs in 
the database.  
Association of age, gender, and other factors in two groups of DILI 
(mitochondrial and non-mitochondrial mechanisms of toxicity) 
Mitochondrial function declines with aging;13 therefore, we evaluated if reports 
of severe DILI were disproportionately associated with older patient age,  indicating 
potential susceptibility to DILI from mitochondrial mechanisms of toxicity.  
Furthermore, since gender may play an important role in the sensitivity of DILI, we also 
evaluated the frequency of reports according to patient gender.  The mean and 
standard deviation (SD) of patient age were calculated and compared between DILI 
reports caused by drugs associated with mitochondrial mechanisms of toxicity and 
DILI reports associated with non-mitochondrial mechanisms. Patient age was 
dichotomized into ≤ 65 years or > 65 years for comparison. Other factors, including 
drug severity class, patient weight, report type, and label section, were examined in a 
descriptive analysis.  
Statistical Analysis:  
Descriptive statistics were used to compare the gender and age of reports for 
the DILI drug groups associated with mitochondrial mechanisms of toxicity and 
associated with non-mitochondrial mechanisms.  The statistical significance of 
differences in categorical variables such as age group, DILI severity, drug label, and 
report type between two categories of DILI drugs was examined using the chi-square 
test. Whereas, differences in continuous variables such as mean patient age between 
the two categories of hepatotoxic drugs were compared with the two-tailed student’s 
t-test for independent samples.  The unadjusted association of age and gender with 
mitochondrial mechanisms of toxicity DILI group (against non-mitochondrial 




analysis.  ROR calculations were carried out using a two-by-two contingency table 
using OpenEpi (version 3.01; Centers for Disease Control and Prevention), which 
calculates 95% CI and p-values via Taylor series.32  Chi-square tests were performed 
with SAS version 9.4 (SAS Institute, Cary, NC), and two-sided t-tests were performed 
at the 0.05 significance level via GraphPad Prism version 8 (La Jolla, CA). All statistical 






















2.4 RESULTS  
We included 192 drugs classified as having the highest DILI risk (“Most-DILI 
concern”) via the NCTR-LTKB database. Out of these 192 drugs, 134 drugs had 
searchable FAERS reports, while the remaining 58 drugs were either withdrawn before 
our study period or were withdrawn from the European market before US approval.  
Therefore, the final data set contained 134 drugs, which were categorized as 56 drugs 
causing hepatotoxicity via mitochondrial mechanisms, and 78 drugs were classified as 
causing hepatotoxicity via non-mitochondrial mechanisms.   
Table 3 indicates the characteristics of the event reports included in the study. A 
total of 104,701 adverse event reports were extracted from FAERS for the period 
spanning January 1998 to May 2019. Of these, 40,343 (38.5%) reports of 
hepatotoxicity were for drugs that were associated with mitochondrial mechanisms of 
toxicity, whereas 64,358 (61.5%) reports of hepatotoxicity were for drugs associated 
with non-mitochondrial mechanisms of toxicity.  Furthermore, drugs were categorized 
based on the NCTR-LTKB severity classification.  There was a statistically significant 
difference in DILI severity (p < 0.0001) between the two groups of DILI drugs 
(mitochondrial mechanisms compared to non-mitochondrial mechanisms).  There was 
a 5.5 percentage point difference in reports for more severe DILI (liver 
failure/hepatotoxicity) for drugs associated with mitochondrial mechanisms of toxicity 
compared to non-mitochondrial mechanisms (76.3% compared to 70.8%, respectively, 
p < 0.0001). As shown in Table 3, the FAERS reports were classified based on the 
drug label section for liver injury; there was a statistically significant difference in drug 
labels (p < 0.0001) between the two groups of DILI drugs (mitochondrial mechanisms 
compared to non-mitochondrial mechanisms). Additionally, 24.6% of mitochondrial 
mechanisms of toxicity drugs had a box warning label as compared to 19.8% of non-




of toxicity drugs had warning and precautions label as compared to 79.1% of non-
mitochondrial mechanisms of toxicity drugs.  For drugs withdrawn due to 
hepatotoxicity, there were high numbers of reports (n = 4227, 10.5%) for drugs that 
are associated with mitochondrial toxicity mechanisms, compared to a lower number 
of reports (n = 747, 1.2%) for drugs with non-mitochondrial mechanisms of toxicity (p 
< 0.0001). Over 88% of reports were expedited, while the rest of the reports were either 
direct or periodic.  In summary, there was a statistically significant difference between 
drug severity classification, label, and liver injury severity according to the drug’s ability 
to cause toxicity through mitochondrial mechanisms.  
We also examined patient bodyweight, but 79%-81% of the reports did not have 
this information documented. Among the 19%-21% of reports where the bodyweight 
data was present, the average difference between the two groups of DILI drugs 
(mitochondrial compared to non-mitochondrial mechanisms) was only 1.6 kg (68.6 ± 
20.8 compared to 70.2 ± 23.4; p < 0.0001). In this case, the small p-value may be 
because the large sample size overpowered the comparison.  As large numbers of the 
reports were missing bodyweight, further analysis was not performed.  As shown in 
Table 3, a higher percentage of males were the subjects of hepatotoxicity reports via 
mitochondrial mechanisms compared to the subjects of reports involving 
hepatotoxicity via the non-mitochondrial mechanisms (49.1% compared to 37.8%, p < 
0.0001). About 7% to 8.3% of reports were missing information about the patient’s 
gender.   
Table 3 presents the difference in the mean and distribution of age among the two 
groups. The patient’s age was recorded in more than 71% of the reports from both the 
groups.  As shown in Table 3, there was a statistically significant difference (p < 
0.0001) between the mean age of patients with hepatotoxicity in drugs that are 




mitochondrial mechanisms of toxicity (48 ± 19.53 (SD)).  In other words, reports 
involving drugs associated with mitochondrial mechanisms of hepatic toxicity 
displayed a higher mean age than reports for drugs associated with non-mitochondrial 
mechanisms of hepatic toxicity.  
Figure 2 indicates the ROR values of drugs associated with mitochondrial 
mechanisms of toxicity; benzbromarone, troglitazone, isoniazid, rifampin, and 
nimesulide had the highest ROR values in the group.  Figure 3 indicates the ROR 
values of drugs associated with non-mitochondrial mechanisms of toxicity; 
telithromycin, gemtuzumab ozogamicin, mexiletine, dactomycin, and disulfiram had 
the highest ROR values in the group. Table 4 indicates the top 20 drugs with the 
highest ROR values in both groups of hepatotoxicants.  The top 20 drugs with the 
highest ROR values included drugs with either mitochondrial or non-mitochondrial 
injury mechanisms.  The top 4 drugs, which had ROR values higher than 18 
(benzbromarone, troglitazone, isoniazid, rifampin), were associated with mitochondrial 
mechanisms of toxicity.  Furthermore, the top two drugs, benzbromarone, and 
troglitazone were withdrawn from the market.   
Table 5 indicates the RORs between the two groups of drugs that caused liver 
injury via mitochondrial compared to non-mitochondrial mechanisms.  Between the 
two DILI groups, reports for DILI involving mitochondrial mechanisms of toxicity had a 
1.43 (95% CI 1.42-1.45; p < 0.0001) times higher odds compared to drugs associated 
with non-mitochondrial mechanisms of toxicity.  The univariate logistic regression 
model was used after dichotomizing age and gender. Table 6 indicates a statistically 
significant risk association of age or gender with hepatotoxic drugs with mitochondrial 
toxicity mechanisms.  Reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.12-
2.26) times more likely to be associated with older patient age, as compared with 




were 37% less likely to be subjects of liver injury reports for drugs associated with 
mitochondrial mechanisms of toxicity compared to males (Odds Ratio 0.63, 95% CI 
0.61-0.64).  Tables 7 to 13 contain DILI reports, all adverse event reports, ROR, and 
95% Confidence Interval (CI) for all the drugs evaluated in the study.  
Figure 4 indicates the totality of all ROR scores of DILI drugs with mitochondrial 
or non-mitochondrial mechanisms of toxicity.  Drugs from the antineoplastic, antiviral, 
analgesic, antibiotic, and antimycobacterial classes were the top 5 drugs classes 
associated with higher ROR scores. Drugs from the antidiabetic, antiretroviral, anti-
inflammatory, anti-Parkinson, vasoactive, neuroprotective, and antihyperlipidemic drug 
classes (pointed in brown arrow) were primarily associated with mitochondrial 
mechanisms.  Alternatively, leukotriene pathway modulators, alcohol antagonists, CNS 
stimulants, and platelet inhibitor drug classes (pointed in red arrow) were the drugs with 
non-mitochondrial mechanisms having higher RORs.  Figures 5 and 6 categorize these 
two groups of drugs based on the drug label section and severity class. We did not 
observe any notable trend between mitochondrial and non-mitochondrial mechanisms 





2.5 DISCUSSION  
Prediction and characterization for DILI during preclinical drug development and 
post-approval remains a challenge for the pharmaceutical industry, toxicologists, 
clinicians, physicians, health authorities, and regulators.5  Characterizing DILI has been 
a challenge due to its unpredictability, lack of accurate biomarkers, poorly defined 
pathogenesis, and its potential to cause fatal liver failure.5  In the past two decades, 
drug-induced mitochondrial dysfunction has been established as an important 
contributing mechanism associated with liver, muscle, heart, kidney, and central 
nervous system toxicity.13  Mitochondrial dysfunction is one of the reasons known to 
cause muscle toxicity by HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) 
reductase inhibitor (cerivastatin), cardiovascular toxicity by anthracyclines 
(daunorubicin, doxorubicin, idarubicin), and DILI by an antidepressant (nefazodone), 
antibiotics (isoniazid, ketoconazole(oral)), and anxiolytic (panadiplon) drugs.19, 33-36   
We calculated the ROR for reports of severe hepatotoxicity adverse events 
among drugs with the highest risk for DILI, for drugs having mitochondrial or non-
mitochondrial mechanisms of toxicity.  Brinker et al. indicated that various measures of 
disproportionate reporting of adverse events such as  Proportional Reporting Ratio 
(PRR), Multi-item Gamma Poisson Shrinker (MGPS), and the Bayesian Confidence 
Propagation Neutral Network (BCPNN) had been used in analyses of surveillance 
databases.8  Each of these methods may have different strengths and limitations and 
may lead to different sensitivity and specificity for a drug's risk reporting.8  Various 
health regulatory authorities use different statistical measures for reporting. For 
example, the European Medicines Agency (EMA) uses PRR; FDA and UK's Medicines 
and Healthcare products Regulatory Agency (MHRA) uses MGPS.  Whereas, the 
World Health Organization (WHO) has utilized the BCPNN method for reporting.8  




adverse event-causal associations. It has been suggested that there is not one single 
measure of effect that is superior to the others. 8, 37, 38 Our study utilized reporting odds 
ratios to characterize the frequency of liver injury reports as it is a straightforward and 
frequently used measure for the analysis of FAERS data. 31, 39-43  
The review published by Will et al.13 indicated that the most commonly used 
prescriptions and over the counter medications for geriatric patients had published 
reports of various toxicities linked to mitochondrial dysfunction.13  Our study reported 
that reports for DILI involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI 
1.42-1.45; p < 0.0001) times higher odds compared to drugs associated with non-
mitochondrial mechanisms of toxicity. The ROR scores with the highest risk of liver 
injury based on mitochondrial or non-mitochondrial mechanisms were highest for drugs 
from the antineoplastic, antiviral, analgesics, antibiotics, and antimycobacterial classes. 
This finding agreed with the published literature.  Sonawane et al. indicated that 
antineoplastic, analgesics, and antibiotics were among the top 10 drugs that reported 
severe adverse events in the FAERS database from 2006 to 2014.26  Additionally, our 
study observed that over 88% of adverse reports were expedited, while the rest of the 
reports were either direct or periodic in both drug categories.  This observation also 
agreed with the published literature.  Sonawane et al. also reported that expedited 
reports were the most common and over 72% of all serious adverse events with 
available data on the report type.26  
Antidiabetic, antiretroviral, anti-inflammatory, anti-Parkinson, vasoactive, 
neuroprotective, antihyperlipidemic drug classes were primarily associated with 
mitochondrial toxicity mechanisms. In recent years, an impaired mitochondrial function 
has been documented as one of the critical factors in inflammation, sarcopenia, 
metabolic (obesity, type 2 diabetes, non-alcoholic fatty liver disease), and 




Patients with reduced mitochondrial function occurring as a manifestation of their 
underlying disease state may be more vulnerable to drugs that cause toxicity via 
mitochondrial mechanisms.  Alternatively, antiadrenergic, leukotriene pathway 
modulators, alcohol antagonist, CNS stimulants, and platelet inhibitors were drug 
classes that were primarily associated with non-mitochondrial toxicity mechanisms.   
We identified statistically significant differences (p < 0.0001) in drug severity 
classification, label section for liver injury, and report type between these two 
mechanisms for DILI.  For drugs withdrawn for liver injury, there were a higher number 
of hepatotoxicity reports (10.5%) associated with mitochondrial than non-mitochondrial 
mechanisms (1.2%).  Dykens and Will (2007) noted that 38 marketed drugs withdrew 
from the market between 1994 and 2006.  Among these, for cerivastatin, nefazodone, 
troglitazone, and tolcapone, there was substantial evidence of mitochondrial-induced 
organ toxicity.34  Therefore, our observations agreed with reports in the medical 
literature of drug-induced mitochondrial dysfunction playing an important role in drug 
withdrawal.  Furthermore, Boelsterli and Lim (2007) suggested that several drugs, such 
as amiodarone, dantrolene, diclofenac, isoniazid, lamivudine, leflunomide, mefenamic 
acid, nimesulide, perhexiline, simvastatin, stavudine, sulindac, tolcapone, troglitazone, 
trovafloxacin, and valproic acid, are associated with idiosyncratic DILI with a clear link 
to mitochondrial toxicity.21  Many of these drugs reported a relatively higher ROR in our 
study. 
Our study reported an older mean patient age (56.1 ± 18.33 (SD)) associated 
with reports for drugs that cause DILI via mitochondrial mechanisms compared to 
mean age (48 ± 19.53 (SD)) associated with reports for drugs that cause injury via 
non-mitochondrial mechanisms (p < 0.0001).  This was further substantiated in a 
univariate logistic regression analysis where reports of liver injury were 2.2 (odds ratio: 




compared with reports involving patient ages under 65 years.  This finding is consistent 
with physiological information indicating age as a risk factor for both mitochondrial DNA 
abnormality and increased oxidative stress-related injury.45  There is evidence that 
mitochondrial function declines with age, including the role of mitochondrial DNA 
mutation, increased production of reactive oxygen species, and the dysfunction in 
oxidative phosphorylation pathways.44 The hallmark of mitochondrial aging includes a 
decreased mitochondrial number, reduced mitochondrial function, and individual 
electron transport chain activities.13 Mitochondrial function deteriorates progressively 
with age. Therefore, older age populations may be more vulnerable to hepatotoxic 
drugs associated with mitochondrial mechanisms of toxicity.   
Our study indicated that female patients were 37% less likely to report liver 
injury adverse events for drugs associated with mitochondrial mechanisms of toxicity 
compared to males.  There are conflicting reports associating male gender as a 
susceptibility factor for DILI, and a clear link for this association is absent in the 
literature. 21, 47   Several articles allude to the potential involvement of a reactive 
metabolite, and differences in pharmacokinetics, pharmacodynamics, sex hormones, 










2.6 CONCLUSION  
Mitochondria play an important part in DILI, including idiosyncratic liver injury.  
There have been various proposed mechanisms for  mitochondrial involvement in 
DILI.45  There is a gap in the literature describing the differences in clinical outcomes 
for patients who experienced DILI from mitochondrial mechanisms of toxicity as 
compared with non-mitochondrial mechanisms of toxicity drugs.  There are limitations 
in detecting drugs that have mitochondrial liability in the drug development phase of 
the discovery.  For the most part, drug-induced mitochondrial toxicity does not reveal 
itself in animal models due to the young age, lack of genetic divergence, health status, 
and lack of concomitant drug exposure.13 Therefore, drug-induced mitochondrial 
toxicity is often idiosyncratic, meaning it is not predictable until a large population is 
exposed.21, 46   Based on this study, we provide evidence of a higher proportion of 
reports of severe liver injury adverse events among drugs associated with 
mitochondrial mechanisms of toxicity as compared with non-mitochondrial 
mechanisms of toxicity.  Furthermore, we found that reports of liver injury were 2.2 
(odds ratio: 2.2, 95% CI 2.12-2.26) times more likely to be associated with older patient 
age, as compared with reports involving patients ages under 65 years.  This finding 
aligns with the theory that age is a susceptibility factor in liver injury via the 











2.7 LIMITATION  
The FAERS database describes adverse event reports but does not include 
information about the number of patients treated with a drug.  Therefore, incidence 
rates, prevalence rates, and causal relationships between drugs and safety adverse 
events cannot be determined for drugs according to mitochondrial or non-
mitochondrial mechanisms of toxicity. For example, the population incidence of DILI 
may be higher for drugs associated with non-mitochondrial mechanisms than 
mitochondrial mechanisms of toxicity. Nevertheless, researchers and health 
authorities have used the FAERS database for adverse event signal identification, 
developing ideas, and hypothesis generation despite this limitation.  The hypothesis 
and ideas generated using this database could serve as a foundation for more robust 
study designs, and for in vitro or in vivo studies investigating the causal relationship of 
a drug with liver injury.  The FAERS database provides a suitable source to evaluate 
the volume and characteristics of adverse event reports for marketed medications.  
Furthermore, factors such as age, gender, weight, drug severity class, and label 
section of FAERS reports can provide valuable insights to health authorities during the 
post-market surveillance of marketed medications.   
The FAERS database is a spontaneous reporting system with limitations when 
used for drug safety research, including the potential for under or over-reporting events, 
duplicate reports, influence of media, and uncertainty of reported events.8, 48 For 
example, troglitazone received significant media attention due to a class-action lawsuit 
which called attention to its DILI risk.  Therefore, troglitazone may have a higher 
number of hepatotoxicity reports than some drugs that did not receive media attention.  
Moreover, the FAERS database could be associated with the "Weber effect," where 




Patients with an underlying condition such as obesity may be more vulnerable 
to drugs that cause toxicity via mitochondrial mechanisms; thus, we attempted to 
include patient weight in our study.  However, about 79-81% of the reports missed the 
bodyweight information; therefore, the effect of patient weight was not examined. The 
study may also have several unmeasured confounding factors as patient comorbidities, 
pre-existing liver disease, and concomitant drug use is not captured in FAERS reports.  
Additionally, the findings regarding age and gender are unadjusted; therefore, it should 
be used merely for hypothesis generation.  Moreover, gender bias may be due to 
disease demographics. Some of the DILI drugs with mitochondrial toxicity mechanisms 
are prescribed for diseases with a higher male predisposition.  For example, 
benzbromarone is prescribed for gout, which has six times higher occurrence in 
males.49 Similarly, isoniazid and rifampin are prescribed for the treatment of 
tuberculosis, which has two times higher occurrence in males.50 
ROR depends on the reporting rates of liver injury adverse events and all other 
adverse events reports in compared drug classes.  DILI drugs associated with non-
mitochondrial mechanisms of toxicity have a significantly higher number of non-hepatic 
adverse events reports.  Therefore, we are not sure if larger ROR values are due to 
the higher reporting of hepatotoxicity in the drugs with mitochondrial mechanisms of 
toxicity, or higher reporting of non-hepatic adverse events reported for the drugs with 
non-mitochondrial mechanisms of toxicity.   
For this analysis, we utilized ROR, which is a disproportionality measurement 
of spontaneous reports and not a method to measure drug-related risks quantitatively. 
Regulatory actions in response to safety concerns related to age and gender using the 
FAERS database must be determined via individual cases to determine causality.  
Despite these database limitations, we were able to show that drugs that cause 




of adverse event reports than drugs having non-mitochondrial mechanisms of toxicity.  
Additionally, age may play a role in susceptibility to DILI via mitochondrial mechanisms 
of toxicity. Our findings from this study align with mitochondrial mechanisms of toxicity 
being an important cause of DILI, and this should be further investigated in real-world 
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2.9 TABLES AND FIGURES 
Table 1.  Reporting odds ratio estimates for DILI drug groups. 
 
Reporting odds ratio estimates for DILI drug groups 
FAERS Reports (N)   





Drugs associated with mitochondrial 
mechanisms of toxicity 
40,343 586,989 627,332 
Drugs associated with non-
mitochondrial mechanisms of toxicity 
64,358 1,342,486 1,406,844 

























Table 2. Example reporting odds ratio estimate for an individual drug: 
acetaminophen. 
 
 Reporting odds ratio estimates for an individual drug  
FAERS Reports (N)   
  Hepatotoxicity 
All other Adverse 
Events 
Total 
Acetaminophen 8,509 51,732 60,241 
All other drugs of 
any type 
383,540 27,852,908 28,236,448 
















Table 3.  Characteristics of patients and hepatotoxic drugs associated 
with mitochondrial mechanisms of toxicity compared to non-
mitochondrial mechanisms.  
 








mechanism (78 drugs) 
FAERS Report Counts (N) 40,343 (38.5%) 64,358 (61.5%) 
Reports based on NKTR drug severity classification  
3 - Liver aminotransferases 
increase 
0 (0%) 3,048 (4.7%) 
4 - Hyperbilirubinemia 1,958 (4.9%) 2,292 (3.6%) 
5 - Jaundice 7,526 (18.7%) 13,392 (20.8) 
6 - Liver necrosis 0 (0%) 35 (0.05%) 
7 -Acute liver failure 4,581 (11.3%) 17,207 (26.7%) 
8 - Fatal hepatotoxicity 26,278 (65%) 28,384 (44.1) 
Reports combined based on less and severe DILI  
Less severe injury 9484 (23.5%) 18,767 (29.2%) 
Liver failure/hepatotoxicity 30,859 (76.5%) 45,591 (70.8%) 
Reports based on drug label section 
Warning & precautions 26,177 (64.9%) 50,898 (79.1%) 
Box warning 9,939 (24.6%) 12,713 (19.8%) 
Withdrawn 4227 (10.5%) 747 (1.2%) 
Report type 
Direct 1,992 (4.9%) 2,393 (3.7%) 
Expedited 35,569 (88.2%) 57,119 (88.8%) 
Periodic 2,782 (6.9%) 4,846 (7.5%) 
Patient Characteristics 
Weight (Kg) 
FAERS Report Counts (N) 7666 (19%) 13532 (21%) 
 Weight Missing 32677 (81%) 50826 (79%) 
Mean ± Stdev 68.6 ± 20.8 70.2 ± 23.4 
Gender 
Male 19,818 (49.1%) 24,353 (37.8%) 
Female 17,711 (43.9%) 34,690 (53.9%) 
Gender Missing 2,814 (7%) 5315 (8.3%) 
Age (Years) 




Age missing 10019 (24.8%) 18046 (28%) 
Mean ± Stdev 56.1 ± 18.33 48 ± 19.53 
A statistical difference between two DILI groups across categorical variables was 
performed using a chi-square test. Comparisons of continuous variables were 























Table 4.  Top 20 drugs with the highest reporting odds ratio in both DILI 
groups.  
 








Antigout agent Benzbromarone 8 Withdrawn Yes 36.31 
Antidiabetic agent Troglitazone 8 Withdrawn Yes 31.02 
Antimycobacterials Isoniazid 8 Box warning Yes 20.79 













8 Box warning No 18.08 
Antiarrhythmics Mexiletine 3 Box warning No 17.8 







Nimesulide 8 Withdrawn Yes 15.07 












Pemoline 8 Withdrawn No 14.24 








8 Withdrawn Yes 13.48 
Antithyroid agents Propylthiouracil 8 Box warning No 13.33 
NSAID Bromfenac 8 Withdrawn No 13.01 
Antiretroviral drugs Stavudine 8 Box warning Yes 12.83 
Hormone modifiers Danazol 8 Box warning Yes 12.82 
Antiparkinson 
agents 
Tolcapone 8 Box warning Yes 12.25 




Table 5. Reporting odds ratio estimate for hepatotoxic drugs associated 
with mitochondrial mechanisms of toxicity compared to non-
mitochondrial mechanisms. 
 
DILI group Odds ratio 95% CI p-value 
Drugs associated with 
mitochondrial mechanisms of 
























Table 6. Unadjusted association of age and gender with hepatotoxic 
drugs with mitochondrial toxicity mechanisms as compared with non-
























variable Odds ratio 95% CI p-value 
Age       
<65 years Reference 
>65 years 2.2 2.12-2.26 <0.0001 
Gender     
Male Reference 




Table 7.  Adverse-event (AE) report counts and risk estimates of DILI for 
analgesics, anti-adrenergic, anti-alcoholic, and antiarrhythmic 
medications. 
 
Drug Class Drug Name 
 
Mitochondri










Yes50 30 229 9.514 
6.502, 
13.92¹  
Analgesics Diclofenac Yes51, 52 350 5647 4.501 
4.04, 
5.014¹  
Analgesics Diflunisal Yes52, 53 2 60 2.421 
0.5917, 
9.902 
Analgesics Etodolac Yes54 105 1823 4.183 
3.436, 
5.092¹  
Analgesics Sulindac Yes55 52 434 8.701 
6.526, 
11.6¹  












No58 6 135 3.228 
1.425, 
7.311¹  






No11 50 391 9.287 
6.918, 
12.47¹  
Analgesics Milnacipran No* 50 2795 1.299 
0.9822, 
1.718 
Antiadrenergic Labetalol No52 47 701 4.869 
3.624, 
6.542¹  





Disulfiram No61 100 490 14.82 
11.95, 
18.38¹  
Antiarrhythmics Amiodarone Yes57 1590 18220 6.337 
6.02, 
6.671¹  
Antiarrhythmics Dronedarone Yes62 444 5433 5.935 
5.387, 
6.538¹  




*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 




Table 8.  Adverse-event report counts and risk estimates of DILI for 
antibiotics, anticonvulsants, antidepressants, and antidiabetic 
medications. 
 








ROR 95% CI 
Antibiotics Ciprofloxacin Yes63 1299 28830 3.272 
3.095, 
3.459¹  
Antibiotics Clarithromycin Yes64 1225 18499 4.809 
4.538, 
5.096¹  






Yes65 1168 6291 13.48 
12.67, 
14.35¹  
Antibiotics Minocycline No* 604 4973 8.82 
8.105, 
9.598¹  
Antibiotics Telithromycin No66 1049 4157 18.33 
17.12, 
19.61¹  
Anticonvulsants Carbamazepine Yes67, 68 1606 22379 5.212 
4.954, 
5.483¹  
Anticonvulsants Phenytoin Yes67, 68 547 15593 2.548 
2.339, 
2.774¹  
Anticonvulsants Valproic acid Yes68, 69 945 11096 6.185 
5.787, 
6.61¹  
Anticonvulsants Divalproex No* 623 14095 3.21 
2.962, 
3.478¹  
Anticonvulsants Felbamate No70 18 364 3.591 
2.237, 
5.764¹  
Anticonvulsants Fosphenytoin No71 68 981 5.034 
3.937, 
6.436¹  
Anticonvulsants Lamotrigine No52 1849 45375 2.959 
2.824, 
3.1¹  
Antidepressant Clomipramine Yes72 64 1500 3.098 
2.413, 
3.979¹  
Antidepressant Nefazodone Yes14 608 4707 9.38 
8.62, 
10.21¹  
Antidepressant Duloxetine No73 2162 50955 3.081 
2.951, 
3.217¹  














*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 




Table 9.  Adverse-event report counts and risk estimates of DILI for 
antifungals, antigout, antihelmintic, antihyperlipidemic, antiinfectives, 
anti-inflammatory, and antimycobacterial medications. 
 











Antifungals Itraconazole Yes77 566 7403 5.552 
5.097, 
6.048¹  
Antifungals Ketoconazole Yes11, 78 233 4364 3.877 
3.398, 
4.424¹  






No79 26 203 9.301 
6.184, 
13.99¹  
Antifungals Micafungin No80 213 1765 8.764 
7.602, 
10.1¹  
Antifungals Terbinafine No81 1330 12101 7.982 
7.542, 
8.447¹  
Antifungals Voriconazole No82 780 9093 6.229 
5.79, 
6.702¹  
Antigout agent Benzbromarone Yes52 1 2 36.31 
3.293, 
400.4¹  
Antigout agent Allopurinol No83 626 5353 8.493 
7.817, 
9.226¹  
Antigout agent Febuxostat No84 161 3910 2.99 
2.554, 
3.501¹  
Anthelmintics Albendazole Yes85 108 879 8.923 
7.306, 
10.9¹  
Anthelmintics Thiabendazole No86 5 45 8.069 
3.203, 
20.33¹  






Yes57 5522 89525 4.479 
4.358, 
4.604¹  
Antihyperlipidemic Niacin Yes87 219 47451 0.3352 
0.2935, 
0.3828¹  
Antiinfectives Erythromycin No88 154 3753 2.98 
2.536, 
3.501¹  





Nimesulide Yes52, 57 11 53 15.07 
7.873, 
28.85¹  
Antimycobacterials Isoniazid Yes52 678 2368 20.79 
19.09, 
22.65¹  
Antimycobacterials Rifampin Yes24 1291 5029 18.64 
17.54, 
19.82¹  
Antimycobacterials Ethambutol No90 117 847 10.03 
8.268, 
12.17¹  





Table 10.  Adverse-event report counts and risk estimates of DILI for 
antineoplastics medications. 
 











Antineoplastics Asparaginase Yes91 145 1993 5.283 
4.464, 
6.254¹  
Antineoplastics Bicalutamide Yes52 371 4033 6.68 
6.006, 
7.43¹  
Antineoplastics Erlotinib  Yes57 915 42889 1.549 
1.451, 
1.654¹  
Antineoplastics Flutamide Yes44, 52 125 807 11.25 
9.317, 
13.58¹  
Antineoplastics Nilutamide Yes76 24 259 6.729 
4.429, 
10.22¹  
Antineoplastics Oxaliplatin Yes92 1297 19069 4.939 
4.669, 
5.226¹  
Antineoplastics Pazopanib  Yes93 1004 19660 3.709 
3.48, 
3.952¹  
Antineoplastics Sorafenib  Yes11 3815 24782 11.18 
10.8, 
11.57¹  
Antineoplastics Tamoxifen  Yes52, 76, 94 257 6330 2.948 
2.603, 
3.34¹  
Antineoplastics Bexarotene No95 14 575 1.768 
1.041, 
3.004¹  
Antineoplastics Bortezomib No96 771 24288 2.305 
2.146, 
2.477¹  
Antineoplastics Busulfan No52 625 3783 12 
11.02, 
13.06¹  
Antineoplastics Cytarabine No97 575 7603 5.492 
5.045, 
5.978¹  
Antineoplastics Dacarbazine No98 35 821 3.096 
2.207, 
4.342¹  
Antineoplastics Dactinomycin No99 200 842 17.25 
14.78, 
20.13¹  
Antineoplastics Estramustine  No100 54 719 5.454 
4.136, 
7.192¹  
Antineoplastics Exemestane No101 312 6728 3.368 
3.006, 
3.773¹  
Antineoplastics Gefitinib No102 798 8074 7.178 
6.674, 
7.719¹  






No104 1067 4286 18.08 
16.91, 
19.33¹  
Antineoplastics Hydroxyurea No52 129 3109 3.013 
2.527, 
3.594¹  


















Antineoplastics Mercaptopurine No52 278 2051 9.843 
8.684, 
11.16¹  
Antineoplastics Pentostatin No* 43 403 7.749 
5.658, 
10.61¹  




*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 




















Table 11.  Adverse-event report counts and risk estimates of DILI for 
antiparkinson, antipsoriatics, antipsychotics, antiretroviral, antithyroid, 
and antiviral medications. 
 








ROR 95% CI 
Antiparkinson 
agents 
Tolcapone Yes76 179 1061 12.25 
10.46, 
14.35¹  
Antipsoriatics Acitretin No107 167 2754 4.404 
3.767, 
5.148¹  































No112 812 6685 8.82 8.20,9.48¹  
Antivirals Didanosine Yes113 557 2812 14.38 
13.13, 
15.75¹  
Antivirals Efavirenz Yes114 760 7903 6.984 
6.482, 
7.524¹  












No116 418 4238 7.163 
6.478, 
7.92¹  






No* 92 1273 5.248 
4.247, 
6.485¹  






No116 414 6012 5.001 
4.527, 
5.525¹  




*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 




Table 12.  Adverse-event report counts and risk estimates of DILI for 
biologics, and disease-modifying antirheumatic medications. 
 








ROR 95% CI 






Acetazolamide Yes68, 69 26 768 2.459 
1.663, 
3.634¹  
Chelators Deferasirox No120 1933 27136 5.173 
4.939, 
5.418¹  







































*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 






Table 13.  Adverse-event report counts and risk estimates of DILI for 
diuretics, gastrointestinal, hematinics, hormone modifier, 
immunomodulators, leucoxene antagonists, musculoskeletal, 
neuroprotective, NSAID, CNS stimulants, and vasoactive medications. 
 








ROR 95% CI 





Bosentan No11 2125 41452 3.723 
3.564, 
3.889¹  






No127 596 10450 4.142 
3.813, 
4.498¹  
Hormone modifiers Danazol Yes52 45 255 12.82 
9.335, 
17.59¹  






No129 15 138 7.894 
4.633, 
13.45¹  
Hormone modifiers Oxymetholone No130 17 122 10.12 
6.093, 
16.81¹  













No* 2018 31442 4.661 
4.455, 
4.876¹  




















Tizanidine No* 133 2125 4.545 
3.815, 
5.416¹  
Neuroprotective Riluzole Yes135 75 935 5.825 
4.604, 
7.37¹  
NSAID Bromfenac  No136 670 3739 13.01 
11.99, 
14.13¹  





















*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion 


























Figure 1. Reporting odds ratios for hepatotoxic drugs having 
mitochondrial mechanisms of DILI. 































































Figure 2. Reporting odds ratios for hepatotoxic drugs having non-
mitochondrial mechanisms of DILI. 
 





















































































Figure 3.  Sum of all ROR of “most-DILI concern” drugs associated with 











Figure 4.  Categorization based on liver injury drug label for “most-DILI 
concern” drugs based on their association with mitochondrial and non-









Figure 5.  Categorization based on liver injury severity class for “most-
DILI concern” drugs based on their association with mitochondrial and 
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Compared to typical antipsychotics, atypical antipsychotic (AAP) drugs have improved 
safety profiles and rarely cause liver injury.  However, no retrospective cohort studies 
have evaluated the short-term risk of liver injury associated with specific AAPs using 
an administrative database in the United States.  
Goal 
This study aimed to identify significant risk factors of liver injury in patients taking 
olanzapine, quetiapine, risperidone, or ziprasidone compared to aripiprazole. First, we 
determined the cumulative incidence rate of liver injury for each AAP among newly 
treated patients.  Among these patients, we also investigated the association between 
liver injury and type of AAP, controlling for various risk factors (age, gender, and 
comorbidities)  
Methods  
We conducted a retrospective cohort study using an administrative claims database to 
identify adults prescribed AAPs from 2010-2015.  The new AAP user cohort was 
selected based on a 12-months pre-index period with no AAP use, followed by a 2-
months AAP exposure period.  ICD9 diagnosis codes were analyzed to identify liver 
injuries (as a composite outcome), including liver enzyme elevation, jaundice, hepatitis, 
cholestasis, cirrhosis, liver necrosis, or acute liver failure occurring during the ten 
months follow-up period.  The demographic and clinical characteristics of patients 
prescribed AAP medications and liver injury outcome groups were examined and 
adjusted for covariates.  The cumulative incidence rates of liver injury among patients 
taking AAP in outpatient and inpatient settings were calculated.  Univariate and 
multivariate logistic regression analyses were utilized (including odds ratio, 95% 





Overall, the cumulative incidence rate of liver injury in various AAP therapies ranged 
from 15.2 to 25.1 per 1000 persons per year. There was no significant association 
between exposure to any of the AAP medications with the composite outcome.  As 
over 90% of the patients over the age of 76 were prescribed dosages of AAPs that 
were below the daily recommended doses, a sensitivity analysis was conducted that 
included only patients 75 years and younger.  This analysis showed that quetiapine 
was associated with 22% (adjusted Odds Ratio (aOR) 1.22, CI 1.04-1.44, p = 0.02) 
increased risk of liver injury as compared with aripiprazole.  Having 1 to 3 comorbidities 
(aOR 1.27, CI 1.09-1.48, p = 0.003) or 4 to 10 comorbidities (aOR 1.57, CI 1.22-2.02, 
p = 0.0004) was associated with 27% or 57% increased risk of liver injury as compared 
with no comorbidities, respectively.  Comorbidities such as documented alcohol abuse 
(aOR 1.63, CI 1.27-2.08, p <0.0001), hypertension (aOR  1.46, CI 1.23-1.73, p 
<0.0001), obesity (aOR  1.36, CI  1.12-1.65, p = 0.002), and hyperlipidemia (aOR 1.31, 
CI 1.1-1.54, p = 0.0012) were associated with increased risk of liver injury.  Anxiety 
diagnosis (aOR 1.2, CI 1.03-1.38, p = 0.021) was associated with a 20% increased risk 
of liver injury.  
Conclusion 
This retrospective cohort study determined the cumulative incidence rate of liver injury 
as 15.2 to 25.1 per 1000 persons per year among patients newly treated with AAP 
medications. Compared to aripiprazole, quetiapine was associated with a 22% 
increased risk of liver injury during the first months of treatment in patients 75 years 
and younger. Various comorbidities, including alcohol abuse, hypertension, obesity, 






Drug-induced liver injury (DILI) is one of the leading reasons for clinical 
candidate termination during drug discovery and development.  Similarly, many drugs 
have received a black-box warning or were withdrawn from the market due to DILI.1, 2  
It is reported that DILI is the 4th leading cause of liver disease leading to liver failure.1  
Many drug classes are associated with DILI, including nonsteroidal anti-inflammatory 
drugs (NSAID), antiepileptic, anti-lipidemic, anti-infective, oncology, 
immunosuppressive, and psychotherapeutic drugs.3, 4  There has been literature 
evidence of liver injury for psychotherapeutic drug class.5 Antipsychotics are broadly 
categorized into two types: typical or atypical.   Antipsychotic drugs, which are mainly 
prescribed for psychotic disorders, including schizophrenia, psychosis, depression, 
insomnia, aggression, anxiety, and bipolar disorder 6, 7 have been implicated with 
clinical hepatotoxicity.5   
Atypical antipsychotics (AAP) have been associated with a variety of adverse 
side effects including weight gain (obesity), metabolic diseases, and nonalcoholic fatty 
liver disease.8, 9 Patients treated with antipsychotic drugs such as chlorpromazine and 
clozapine have increased risk of mild to severe liver injuries.10, 11  Derby et al. (1993) 
conducted a cohort study of over 10,000 users of chlorpromazine in the United 
Kingdom (UK).12  They reported that chlorpromazine was associated with DILI with a 
frequency of 1.3/1000 users (95% CI; 0.8-2.2).12  More recently, De Abajo et al. (2004) 
performed a population-based study in the United Kingdom of over 1.6 million subjects 
from 1994 to 1999; they reported that chlorpromazine had the strongest association 
with liver enzyme elevations, with an adjusted odds ratio (aOR) of 416 (95% CI; 45-
3840).11  Furthermore, several case-control studies reported an association of 
antipsychotics with liver injury. 10, 13  It is believed that, compared to typical 




only rarely cause liver injury.5  However, despite their potentially safer profile, 
asymptomatic increases in transaminase liver enzymes and bilirubin have been 
reported.5 When occurring, elevated liver enzymes typically appear after six weeks of 
AAP treatment, and levels tend to disappear with drug withdrawal.5, 14 There are also 
reports of AAP inducing liver function abnormalities in the clinical setting.6  Hence, 
clinical guidelines for liver enzymes measurement during, and initiation of the AAP 
drug therapy have been put in place.5 
To our knowledge, there are no retrospective cohort studies that evaluated 
clinical liver injury risk of AAP during the initial treatment months using a geographically 
diverse US database.  This study examined the liver injury risk of various AAP 
medications and liver injury risk factors among newly treated patients.  Strong 
associations between liver injury and particular AAP types as identified in real-world 
research such as this study, might help prescribers select appropriate AAP medications 
for patients at higher risk.  These study results may help clinicians understand liver 
injury risks in balance with drug therapy, improve therapy adherence, and monitor for 
liver injury.  Furthermore, additional information about liver injury risk among AAPs is 
needed to guide therapeutic monitoring protocols and more readily identify medication-
related causes.  
This study aimed to identify significant risk factors of liver injury in patients 
taking olanzapine, quetiapine, risperidone, and ziprasidone compared to aripiprazole. 
First, we calculated the cumulative incidence rate of liver injury among patients newly 
treated with AAP medications.  Then we estimated the risk of liver injury among patients 
newly treated with AAPs in a multivariable framework that controlled for various risk 
factors (age, sex, and comorbidities), using a retrospective cohort study based on a 







Data Source:  
The Optum Clinformatics Data Mart (OptumInsight, Eden Prairie, MN) is an 
administrative health claims database from a large national insurer. Our study 
analyzed claims from January 1, 2010, to December 31, 2015.  For the study, the 
Optum database containing de-identified data on age, geographic location, drugs, 
inpatient and outpatient services, medical services, eligibility, and pharmacy claims 
were used; Institutional Review Board (IRB) approval number was IRB1920-030.  The 
data contain information on member eligibility, medical claims, facility detail, 
prescription claims, inpatient confinement, provider, and death date.  For this study, 
lab results and death data were not utilized.  The wide geographic representation and 
size of the database serve as a valuable tool to examine liver injury risk in real-world 
settings.  Inpatient and outpatient medical claims included diagnosis codes based on 
the International Classification of Diseases 9th (ICD9).  Clinical procedures (e.g., 
laboratory testing) are recorded using the Current Procedural Terminology (CPT) 
codes 
Cohort selection:  
Drugs under the psychotherapeutic medication class of American Hospital 
Formulation Service (AHFS – 28:16 (psychotherapeutic agents)) were used for cohort 
selection. AHFS – 28:16.08.04 (Atypical Antipsychotics), a pharmacologic therapeutic 
classification, for AAP were used for the study cohort.  The cohort included patients 
who were newly treated with an AAP medication between January 1, 2011, to March 




following a pre-index period (spanning January 1, 2010, to January 1, 2014) of 12-
months without antipsychotic therapy.   
 Figures 1 and 2 indicate the schematic diagram of the study design and the 
final cohort selection exclusion criteria, respectively.  Patients were excluded from the 
study if they meet any of the following criteria: 1) were prescribed any typical or atypical 
antipsychotic medications in the pre-index period, 2) had less than 12-months of 
continuous enrollment before and following the index period, or were not continuously 
eligible for health and pharmacy benefits during the entire pre-index or exposure 
periods, 3) were less than 18 years of age as of the index date, 4) had a liver injury or 
HIV diagnosis at any time during their pre-index period or in the exposure period (60 
days after the index date), 5) did not have at least two prescription claims for AAP 
during the exposure period, 6) were dispensed chronic concomitant drugs that were 
highly associated with liver injury based on LiverTox database.   
Bjornsson (2016) published various drug classes that had been implicated with 
DILI.  The article categorized drugs from the publicly available LiverTox database 
(http://livertox.nlm.nih.gov) into different groups based on their likelihood of causing 
hepatotoxicity.15  Category A was  DILI drugs as having more than 100 published case 
reports of hepatotoxicity.15  In this study, we excluded patients prescribed chronic 
concomitant medicines that had a high likelihood of causing liver injury.  If the patients 
were prescribed one or more category A DILI drugs with an increased liver injury 
association, they were excluded from the study.  The patients prescribed concomitant 
drugs allopurinol, amiodarone, azathioprine, carbamazepine, dantrolene, disulfiram, 
flutamide, hydralazine, isoniazid, ketoconazole, methotrexate, methyldopa, 
minocycline, phenytoin, propylthiouracil, quinidine, rifampin, sulfasalazine, ticlopidine, 
valproate or valproic acid were excluded from the study.15 




AAP medication users were defined as having received at least two 
prescription claims for any quantity and duration during the exposure period. They 
were monitored for liver injury diagnosis for the subsequent ten months following the 
exposure period.  The exposure period ended on the 60th day from the index day.   
Selection of control group:  
The most frequently prescribed AAPs prescribed were olanzapine, quetiapine, 
risperidone, ziprasidone, and aripiprazole.  A review published by Telles-Correia 
(2017) examined psychotherapeutics and liver injury, they did not describe any liver 
injury reports for aripiprazole.5 Therefore, aripiprazole was used as a reference.  On 
the other hand, olanzapine, ziprasidone, risperidone, and quetiapine had reports of 
liver enzyme elevations or other liver injuries.5   
Covariates:  
A variety of demographic and clinical characteristics were examined, including 
patient age, gender, health plan type, geographic location, comorbidities,  and disease 
burden (Elixhauser comorbidity index) 16, 17 associated with the indexed prescription 
during the pre-index period.  Patients taking AAP may have several comorbidities; 
therefore, the Elixhauser comorbidity measures could help with risk assessment of 
safety data.  The Elixhauser index utilizes 31 conditions using predictors of mortality 
in patients with cardiac, gastrointestinal, hepatobiliary, oncologic, hypertension, 
obesity, weight loss, and psychiatric conditions.18 
The clinical practice guidelines from the European Association for the Study of 
Liver (EASL) indicated that older age, female gender, alcohol intake, and comorbidities 
(metabolic disease, chronic hepatitis) might be risk factors for DILI.19  Based on the 
evidence supported by several published articles, the study investigated various 




hyperlipidemia, renal disease, and cardiovascular disease associated with liver injury 
among patients newly treated with AAP medications. 20-23 
The study included new users of AAP drug therapy only.  Therefore, they are 
expected to be initiated on lower doses of AAP medications. New patients are usually 
prescribed low dose therapy and then gradually increase the dose based on the 
effectiveness and side effects. Given that the AAP drug class has diverse 
physicochemical drug properties, different drug concentrations in the human plasma 
level (Cmax) are needed to achieve optimum drug effects.24  Various adult daily doses 
such as 10-30 mg for olanzapine, 300-800 mg for quetiapine, 2-6 mg for risperidone, 
10-30 mg for paliperidone, 10-30 mg for aripiprazole, and 80-160 mg for ziprasidone 
are recommended.25   
Although AAP medications were primarily approved for schizophrenia, these 
drugs are also prescribed for other neuropsychiatric disorders such as bipolar disorder, 
psychosis, depression, anxiety, insomnia, and aggression.7  ICD9 codes (as shown in 
Table 1) were used to determine the diagnosis for AAP medications prescription for 
the cohort (14 days prior and following the index day).  These diagnoses were 
examined as independent variables. 
Outcome Assessment:   
ICD9 diagnosis codes were utilized to identify liver injuries including liver 
enzyme elevation, jaundice, hepatitis, cholestasis, cirrhosis, liver necrosis, or acute 
liver failure occurring during the ten months follow up period; which spanned from 
March 1, 2011, to December 31, 2015.  If a patient was identified with any of the ICD9 
codes from Table 1, they were considered positive for the liver injury outcome.   There 
was one composite outcome score (yes or no) for liver injury outcome.  There are 
published studies for the administrative claim database utilized these diagnosis codes 




using these ICD9 codes with 53%-98% sensitivity and 59-98% accuracy.17 Bui et al. 
reported positive predictive values from 48-84% for liver injury diagnosis codes.28 
Sensitivity Analyses: 
Sensitivity analysis to include patient’s population prescribed therapeutic doses 
Patients aged 76 and older are more likely to be prescribed lower doses, and 
use AAPs on an as-needed basis, for example when used for off-label indications such 
as agitation or insomnia. To investigate this issue, we examined the AAP doses 
prescribed among patients ages 76 and older and found that a majority received 
substantially lower doses than described in the FDA label. Therefore, this population 
was excluded from the study cohort in a sensitivity analysis that examined the risk of 
liver injury among patients who were generally prescribed AAPs at usual recommended 
doses.  
Sensitivity analysis – Liver injury models based on liver enzyme exclusion and 
most severe liver injury 
Additional to the composite liver injury outcome, we also conducted analyses to 
include only more severe forms of liver injury as the outcome, e.g., cases who had 
jaundice or worse (excluding liver enzyme elevations) and the outcome of most severe 
liver injury cases, including liver necrosis and acute liver failure. 
Statistical Analysis:  
Baseline demographic characteristics between groups were evaluated.  In this 
analysis, the differences of categorical variables, various demographic and clinical 
characteristics, between different AAP users were compared using a chi-square test. 
A comparison of a continuous variable, such as age, was performed using a student’s 
t-test for independent samples.  In this study, the cumulative incidence rate was 
calculated by dividing the number of new cases of liver injury events in the population 




The study utilized a stepwise logistic regression model via backward 
elimination to choose the statistically significant independent variables associated with 
liver injury.  The study used univariate and multivariable analysis.  The univariate 
analysis evaluated the unadjusted association between the liver injury outcome and a 
single variable. In contrast, the multivariable analysis assessed the adjusted 
association between liver injury outcomes with several variables simultaneously.29, 30 
Before the multivariable analysis, collinearity assessment of independent variables 
was performed using the variation inflation factor and condition index.  Collinearity 
assessment determined that there were no variables that were highly correlated 
(variation inflation factor greater than 5 or conditional index greater than 30).   
Model development started with a univariate logistic regression analysis 
(based on liver injury outcome: no or yes) and reported odds ratios, 95% CI, and p-
values. The variables with less than 0.1 p-values were further included in the 
multivariable logistic regression analysis. The AAP drug type, age, and gender were 
included in the multivariable model throughout.  For the rest of the covariates, a 
stepwise multivariable logistic regression model via backward elimination was utilized 
to choose the most statistically significant variables after removing insignificant 
variables with p-value ≥ 0.05.29, 31   
The Hosmer and Lemeshow goodness-of-fit test was used to determine the 
performance of the model in this study. If the p-value is higher than 0.05, the model 
fits appropriately with no significant difference between observed and predicted 
values.30  The Area Under Curve – Receiving Operating Curve (AUC-ROC) method 
was used to identify the optimal model that predicts the liver injury outcome.  AUC-
ROC is a plot of sensitivity vs. 1-specificity. 30, 32, 33  SAS version 9.4 (SAS Institute, 
Cary, NC) was used to perform all the analysis, and all statistical tests were two-sided 




3.4 RESULTS  
Study cohort 
As shown in Figure 2, we selected 669,972 patients prescribed AAP 
medications from January 1, 2010 to December 31, 2015.  We excluded 40,262 
patients who were prescribed AAP medications during the pre-index period (12-
months before the index date),  519,863 patients  had less than 12-months of 
continuous enrollment prior to or following the index period, 11,157 patients were 
younger than 18 years of age, and 5,810 patients had a liver injury or HIV diagnosis 
during the pre-index or exposure period.  As described in the cohort selection section, 
we excluded 33,465 patients who were also prescribed chronic concomitant 
medications implicated in DILI during the pre-index or exposure period.  Therefore, 
after applying all exclusion criteria, the final cohort contains 44,414 patients who were 
dispensed the most frequently used AAP medications, including quetiapine (41.4%), 
aripiprazole (27.5%), risperidone (20.5%), olanzapine (8.6%), and ziprasidone (2%).  
Demographic and clinical characteristics of the study population 
A detailed description of demographic and clinical characteristics of the study 
population is presented in Table 2 (A, B, C).  Overall, more than 36% of patients were 
between the ages of 41 and 65, followed by 31.3% of patients over 76.  A large 
proportion of the study population (66.1%) were female. Most of the patients (40.3%) 
enrolled to a health maintenance organization plan, followed by 34.7% of the patients 
who had a point of service plan.  There were similar proportions of patients with 
commercial (52.8%) and Medicare (47.2%) insurance type. Most of the patients were 
in the south (43.3%) and the west (28.6%) geographic region. About 79% of patients 
had diagnoses other than schizophrenia, psychosis, major depressive, bipolar 
disorder, or anxiety. The top comorbidities in the study population were hypertension 




(18.7%).  Approximately 45% and 9% of the patients had Elixhauser comorbidity 
scores of 1-3 and 4-10, respectively, indicating that over half of the population 
consisted of patients with at least one comorbidity.   
Liver injury incidence rate for AAP medications  
 
Table 3 indicates the cumulative incidence rate of liver injury in patients taking 
AAP medications, combining diagnoses from outpatient and inpatient settings.  
Overall, the cumulative incidence rate per 1000 persons over 10 months was 15.3. 
The cumulative incidence rate of various AAP therapies ranged from 12.7 to 20.9.  
Based on the cohort selected, ziprasidone had the highest incidence rate of 20.9; 
alternatively, risperidone had the lowest incidence rate of 12.7 per 1000 persons over 
10 months.  Liver injury diagnosis was further characterized by the severity of the 
injury. Overall, cholestasis or cirrhosis liver injury was the most frequent type of liver 
injury reported, representing 44.8% of all types of liver injuries documented during the 
follow-up period. On the other hand, liver necrosis was least frequently reported 
(3.4%). Similar trends were observed for particular AAP types, where cholestasis or 
cirrhosis represented 39.6% to 46.2% of documentations of liver injury, while liver 
enzyme elevations ranged from 24.5% to 34.1% of documented liver injuries. Acute 
liver failure, the most severe form of liver injury, represented 24.2% to 31.2% of 
documented liver injuries.  It is important to note here that a patient can report more 
than one form of liver injury during the period observed. 
Liver injury outcomes using univariate logistic regression modeling 
 
The univariate logistic regression models were used after dichotomizing the 
individual demographic variables such as age, gender, type of health plan and 
insurance, and geographic region. Moreover, the comorbidities were selected based 
on published research on the association of these factors with liver injury risk.  The 




collinear; therefore, all the variables were further included in univariate and 
multivariable logistic regression analyses.   
Table 4 includes the unadjusted odds ratios, number of patients with or without 
liver injury diagnosis, 95% confidence intervals, and p-values of the univariate 
regression models for liver injury outcomes.  Overall, there were low numbers of cases 
(1025; 2.3%) of patients with liver injury diagnosis as compared with the number of 
patients without liver injury (43,389; 97.7%).  Based on the model, p-values were less 
than 0.1 for age, type of health plan and insurance plan, geographic region, various 
diagnosis near index date, patient comorbidities, and Elixhauser comorbidity index.  
Although p-values were greater than 0.1 for various AAP medications and gender, they 
were included in the multivariable model given the importance of these variables to the 
analysis.   
Liver injury outcomes using multivariable logistic regression modeling 
To determine the significant predictive variables associated with liver injury 
outcome risk, a multivariable logistic regression model was applied and fitted with 
independent variables, including AAP medication type, age, gender, diagnosis, 
comorbidities, and Elixhauser’s comorbidity index.  Health plan type, insurance type, 
and geographic regions were excluded from the model as they did not show significant 
associations during the multivariable model building process (p > 0.05).  Similarly, 
schizophrenia/psychosis diagnosis, other diagnoses near index date, type 2 diabetes 
comorbidity, and renal disease comorbidities were also removed due to their lack of 
statistical significance during model building (p > 0.05).  As shown in figure 3 and Table 
5, having 1 to 3 comorbidities (aOR 1.36, CI 1.17-1.56, p < 0.0001) or 4 to 10 
comorbidities (aOR 1.59, CI 1.27-1.97, p < 0.0001) were associated with 36%, and 
59% increased risk of liver injury, respectively.  Similarly, comorbidities such as alcohol 




p < 0.0001), obesity (aOR  1.35, CI  1.12-1.61, p = 0.002), hyperlipidemia (aOR  1.27, 
CI 1.1-1.47, p = 0.0013), and cardiovascular diseases (aOR 1.26, CI  1.08-1.47, p = 
0.0027) were associated with increased risk of liver injury.  Major depressive or bipolar 
disorder diagnosis (aOR 1.17, CI 1.01-1.35, p = 0.032) or anxiety diagnosis (aOR 1.2, 
CI 1.03-1.37, p = 0.022) was associated with 16%, and 20% increased risk of liver 
injury.  Patients aged 76 or older (aOR 0.45, CI 0.35-0.58, p < 0.0001) were associated 
with a 55% decreased risk of liver injury.  AAP therapy and gender were included in 
the multivariable logistic regression model for liver injury risk; however, both variables 
did not significantly associate with the outcome measured.  The Hosmer and 
Lemeshow goodness-of-fit test was performed to determine if the liver injury 
association model fit adequately; the model fit appropriately with a p-value of 0.09.  
Furthermore, the predictive model's assessment was also conducted using ROC-AUC; 
the ROC-AUC value was 0.66, indicating a good predictive model.   
Daily dose distribution of AAP medications in patients ages 76 and older 
Table 6 indicates the daily dose distribution of AAP medications for patients 
ages 76 or older.  For aripiprazole, daily recommended doses are between 10 to 30 
mg, over 90% of the ≥ 76 age patients were prescribed below the daily recommended 
doses (i.e., 2 and 5 mg doses).  The recommended dose of olanzapine is between 10 
to 20 mg daily, approximately 93% of patients age ≥ 76 were prescribed below the 
daily recommended doses (i.e., 2.5 and 5 mg doses).  The recommended dose of 
risperidone is between 2 to 8 mg daily; over 99% of these older patients were 
prescribed below the daily recommended doses (i.e., 0.25, 0.5, and 1 mg doses). The 
recommended dose of ziprasidone is between 40 to 80 mg daily; over 95% of these 
older patients were prescribed below or at the lower end of the daily recommended 




between 300 to 800 mg daily, over 97% of these older patients were prescribed below 
the daily recommended doses (i.e., 25 and 50 mg doses). 
Sensitivity analysis – Predictive variables for liver injury outcomes in patients 
75 and younger 
 As indicated above, >90% of the patients over the age of 76 were prescribed 
below the daily recommended AAP drug doses.  Therefore, in a sensitivity analysis, 
we included only patients age 75 or younger using the same multivariable logistic 
regression modeling approach as previously described.  As shown in Table 7, in this 
model quetiapine was associated with a 22% (aOR 1.22, CI 1.04-1.44, p = 0.02) 
increased risk of liver injury in 75 and younger patients as compared with aripiprazole 
use. Patients having 1 to 3 comorbidities (aOR 1.27, CI 1.09-1.48, p = 0.003) or 4 to 
10 comorbidities (aOR 1.57, CI 1.22-2.02, p = 0.0004) were associated with 27% and 
57% increased risk of liver injury, respectively.  Similarly, comorbidities such as alcohol 
abuse (aOR 1.63, CI 1.27-2.08, p <0.0001), hypertension (aOR  1.46, CI 1.23-1.73, p 
<0.0001), obesity (aOR  1.36, CI  1.12-1.65, p = 0.002), and hyperlipidemia (aOR 1.31, 
CI 1.1-1.54, p = 0.0012) were associated with increased risk of liver injury.  Anxiety 
diagnosis (aOR 1.2, CI 1.03-1.38, p = 0.021) was associated with a 20% increased 
risk of liver injury.  Based on the Hosmer and Lemeshow goodness-of-fit test, the p-
value was 0.17, and the AUC-ROC value was 0.64.   
Sensitivity analysis – More restricted definitions of the liver injury outcome in 
patients 75 and younger 
In addition to the composite liver injury outcome, we also built separate models 
based on liver injury severity.  Table 8 indicates the multivariable model for composite 
liver injury outcomes, excluding elevated enzymes, for the population of patients age 
75 and younger.  Similar to the composite liver injury outcome model, quetiapine was 




Having 1 to 3 comorbidities (aOR 1.32, CI 1.1-1.71, p = 0.002) or 4 to 10 comorbidities 
(aOR 1.78, CI 1.35-2.33, p = <0.0001) were associated with 32% and 78% increased 
risk of liver injury.  Similarly, comorbidities such as alcohol abuse (aOR 1.76, CI 1.35-
2.3, p <0.0001), renal disease (aOR 1.37, CI 1.03-1.83, p = 0.03), hypertension (aOR  
1.57, CI 1.31-1.89, p <0.0001), obesity (aOR  1.38, CI  1.11-1.71, p = 0.003), and 
hyperlipidemia (aOR 1.29, CI 1.08-1.54, p = 0.005) were associated with increased 
risk of liver injury.  Major depressive or bipolar disorder diagnosis (aOR 1.26, CI 1.06-
1.48, p = 0.007) was associated with a 26% increased risk of liver injury.  Based on 
the Hosmer and Lemeshow goodness-of-fit test, the p-value was 0.3, and the AUC-
ROC value was 0.65.  We also examined the most severe liver injury outcomes, 
including liver necrosis and acute liver failure for patients ages 75 and younger.  As 
shown in Table 9, we did not observe any significant association of any particular AAPs 

















3.5 DISCUSSION  
Drug-induced liver injury is rare but can result in life-threatening liver failure, 
potentially leading to death.  DILI was first described over 70 years ago.34 Since then, 
it has become a major concern for clinicians, the pharmaceutical industry, and health 
authorities as more than 1000 drugs have been associated with liver injury.34  Many 
drug classes are associated with DILI; the antipsychotic drug class is one of them. 
Typical antipsychotics were first discovered in the 1950s; whereas, atypical 
antipsychotics were introduced in the 1990s.35  Current studies have reported that 
there has been increased use of AAPs in recent years.36 It is generally believed that, 
compared to typical antipsychotics, atypical antipsychotics have less adverse side 
effects. 5, 35  Also, AAPs have better molecular toxicity profile; they are not associated 
with mitochondrial mechanisms of toxicity.  However, there have been reports of liver 
enzymes and bilirubin elevation along with liver function abnormalities in clinical 
setting.5, 6 Moreover, there is a gap in the literature evaluating the incidence and the 
risk association for AAP in the real-world.   
 Based on the cohort selected in the study, we report that quetiapine (41.4%) 
was the most frequently prescribed AAP. Our reported prescription rate agreed with a 
study that examined the international trends in antipsychotic use.36  The study reported 
that in 2014, quetiapine was the most frequently used AAP in all age groups in most 
of the countries studied.36   Our study cohort was predominantly (>66%) female, and 
over 31% of the cohort was older than  76 years.  This finding was consistent with a 
published report that the prevalence of antipsychotic use has increased by 15% in 
people aged 65 and older.36  We reported that 79% of our cohort patients had 
diagnoses other than schizophrenia, psychosis, major depressive, bipolar disorder, or 
anxiety.  This finding agreed with the published study by Carton et al., who reported 




Based on published literature, AAP-induced severe liver toxicity is rare.   Telles-
Correia (2017) published a review of psychotherapeutics and liver injury, where the 
authors did not report any liver injury reports for aripiprazole.5 Olanzapine, risperidone, 
and quetiapine had reports of liver enzyme elevations.5  Olanzapine and risperidone 
had reports of liver injury via immune mechanisms causing hepatocellular and 
cholestatic lesions.5  We reported the cumulative incidence rate of 15.3 per 1000 
persons over 10 months for AAP medications. Based on the cohort selected, 
ziprasidone had the highest incidence rate of 20.9; alternatively, risperidone had the 
lowest incidence rate of 12.7 per 1000 persons over 10 months.  However, these are 
rates of liver injury of patients who were prescribed AAPs; yet we do not know if the 
liver injury was caused by the AAP.  
To our knowledge, there were no studies that evaluated the cumulative 
incidence rate of liver injury using the claims database.  Liver injury diagnosis was 
further characterized by the severity of the injury.  Of all the liver injuries reported, 
cholestasis or cirrhosis was reported most frequently at the 44.8% of all types reported, 
followed by acute liver failure which represented 28.4% of documented liver injuries. 
Our study reported liver enzyme elevation represented 24.5% to 34.1% of liver injury 
events.  There are conflicting reports for liver injuries enzyme elevation (alanine 
transaminase, aspartate transaminase, and lactate dehydrogenase) with AAP therapy.  
Some reports indicated that liver enzymes' elevation is infrequent or low with AAP 
agents,38, 39 whereas some studies have reported increases in transaminase liver 
enzymes and bilirubin with AAP therapy.5   
 We evaluated AAP therapy in the multivariable logistic regression model for 
liver injury risk; however, it did not significantly associate with the liver injury outcome.  
We believed that it is due to the inclusion of patients 76 ages and older.  We 




the daily recommended doses for all the AAP medications.  In other words, older 
patients in the nursing home facility may be prescribed lower strength AAP 
medications for off-label use of minor symptoms such as agitation or insomnia, and 
likely use the AAP on an as-needed basis (i.e. sporadically). Several studies have 
reported that off-label AAP medications use expected in about ~65% of elderly patients 
(≥ 65 years) from 42 states Medicaid programs;40 additionally, 83% of Medicare claims 
for AAP were associated with off-label conditions and 88% with dementia.41 Moreover, 
older age patients will mostly be in a nursing home setting, which may be closely 
monitored for liver enzyme elevation.  They are more prone to stop AAP drug therapy 
if they show an elevation in liver enzymes. Therefore, we only included patients 75 and 
younger in a sensitivity analysis using multivariable logistic regression modeling.  After 
excluding older age patients (≥ 76 years), quetiapine was associated with a 22% 
increased risk of liver injury.  Similarly, the sensitivity analysis for composite liver injury 
outcomes, excluding elevated enzymes for patients 75 and younger, was performed.  
We found that quetiapine AAP medication was associated with a 22% increased risk 
of liver injury and excluding liver enzyme elevation provided the same risk association 
of quetiapine with liver injury.  Liver enzyme elevations could be due to a variety of 
reasons and could sometimes be transient.  Elevation in liver enzymes does not 
always progress to liver injury outcomes. Vatsalya et al. investigated quetiapine-
induced liver injury (received 12-weeks of therapy)  in heavy alcohol drinking 218 
patients.42 They concluded that quetiapine did not cause liver injury (measured by liver 
enzymes) in patients 18-65 years of age with pre-existing liver injury.42 Furthermore, 
liver injury incidence and severity were low in quetiapine-treated patients.42  Quetiapine 
is associated with mild liver enzyme elevations. However, several case-control studies 
reported patients developing acute liver injury or hepatic failure after receiving 




induced liver injury is reported in several case-control studies but lacks more extensive 
studies. The published reports suggest that quetiapine-induced hepatotoxicity can be 
idiosyncratic, and the mechanism is unknown.46  Based on sensitivity analysis, we did 
not observe any significant association of any AAPs with the severe liver injury 
outcomes, including liver necrosis and acute liver failure.  We believe that the 10-
months of follow-up period may not be sufficient enough to observe severe liver injury 
symptoms. 
 We investigated comorbidities such as hypertension, type 2 diabetes, obesity, 
alcohol abuse, hyperlipidemia, renal disease, and cardiovascular disease associated 
with a liver injury among patients newly treated with AAP medications.20-23  The clinical 
practice guidelines from the European Association for the Study of Liver (EASL) 
indicated that older age, female gender, alcohol intake, and comorbidities (metabolic 
disease, chronic hepatitis) might be risk factors for DILI.19   Quetiapine was associated 
with increased risk of DILI (for patients 75 and younger) for comorbidities; having 1 to 
3 comorbidities or 4 to 10 comorbidities were associated with 27% and 57% increased 
risk of liver injury.  We further reported that comorbidities such as alcohol abuse (63%), 
hypertension (46%), obesity (36%), and hyperlipidemia (31%) were associated with 
increased risk of liver injury.  Hayes et al. performed a population-based cohort study 
using UK health records from 1995 to 2012 in bipolar disorder patients.47 In the study,  
for ~1.5 years of drug treatment duration, there were 67% increased rates of 15% 
weight gain in 1376 patients taking quetiapine (hazard ratio (HR) 1.67, 95% CI 1.24-
2.20, p <0.001).47  Hayes et al. did not observe a statistically significant difference in 
hepatoxicity in quetiapine treatment than lithium.47 In contrast, compared to lithium, 
quetiapine was associated with lower risk of kidney and endocrine adverse events 
(kidney disease HR 0.62, 95% CI 0.47–0.80, p < 0.001; hypercalcemia HR 0.23, 95% 




 Ucok et al. indicated that AAP medication users are associated with a higher 
risk of weight gain, new-onset of diabetes mellitus, hyperlipidemia, prolongation of the 
QTc interval of the electrocardiogram, myocarditis, sexual dysfunction, extrapyramidal 
side effects, and new-onset of cataracts.20 Meyer and Koro (2004) published a review 
indicating that quetiapine (along with olanzapine and clozapine) has been associated 
with a higher risk of hyperlipidemia.48 Atmaca et al. showed that quetiapine was 
associated with increased triglyceride levels in a 6-week prospective study of 
schizophrenia patients (11.64 ± 4.56 mg/dl, p < 0.05).49 Centorrino et al. indicated that 
patients taking psychotropic medications had a higher prevalence of metabolic 





















This retrospective cohort study determined the cumulative incidence rate of liver 
injury 15.2 to 25.1 per 1000 persons per year among patients newly treated with AAP 
medications. Compared to aripiprazole, quetiapine was associated with a 22% 
increased risk of liver injury during the first months of treatment in patients 75 years 
and younger. We propose further prospective real-world studies to substantiate these 
findings.  We propose that patients on quetiapine AAP should be monitored for liver 
enzyme elevations as an early sign of liver injury.  Finally, patients with various 
comorbidities such as alcohol abuse, hypertension, obesity, and hyperlipidemia, should 





















3.7 LIMITATION  
The study used an administrative claims database where the data was collected 
mainly for claim purposes; thus, billing and coding errors may be present.  Studies 
utilizing claims database could be relatively inexpensive; however, there is no control 
over the types of data collected.  Therefore, there may be insufficient or inadequate 
information on exposures, outcomes, and confounders.  Observational retrospective 
cohort studies such as ours are a less robust design than randomized control trials due 
to potential inherent biases; therefore, a causality of scientific mechanism-based 
hypothesis for an AAP-induced liver injury was not possible.  Additionally, increased 
risk or association does not imply causation.  Further study(is) may be necessary to 
evaluate these factors' predictive nature using more robust methodologies and in 
vitro/in vivo mechanistic toxicity studies. Medical claims databases do not contain 
information on potential risk factors such as illicit drug use, over-the-counter drug use, 
and smoking; these additional potential risk factors remain unknown.50  Finally, using 
the claims database allowed drug use assessment based mainly on pharmacy claims;  
the real use patterns of medication use was unknown.   
The study contains fixed exposure and follow up period as we planned to 
evaluate AAP treatment during initial stages where doses are low.  We intended to 
examine the differential risk of liver injury during the treatment initiation phase and not 
over a longer time.  This short-term analysis is adequate as there is no time between 
exposure and outcome; it will enable us to evaluate the temporal relationship between 
exposure and outcome. However, fixed exposure and follow-up period could cause 
selection bias.  Moreover, it is possible that a patient could have a liver injury after one 
or two months of follow up period and could discontinue the treatment.  If patients 
switched to different AAP within the 60-days exposure period, they were excluded from 




days of the exposure period, their outcome was attributed to the AAP initially 
prescribed.   The study assessed the cumulative incidence rate of liver injury between 
AAP among new users with various comorbidities.  Therefore, the underlined 
comorbidities influencing liver injury in the new AAP users cannot be ruled out.  From 
the Optum database, liver function tests were not available; hence, quantitative 
elevation in hepatic enzyme levels was not investigated.  This study only assessed 
short term outcomes (10-months); therefore, the long-term prognosis of drug-induced 
hepatotoxicity and chronic hepatopathy were not evaluated.  This information could add 
value to the study, as in many cases, short-term liver enzyme elevations could be 
reversed and may not necessarily result in long-term liver damage. Moreover, there 
are limitations of using only ICD9 codes to identify adverse events such as liver injury, 
which have poor sensitivity and may lead to underreporting of liver injuries.26 Junjuvadia 
et al. (2007) recommended combining a text search of the dictated medical record with 
ICD9 codes to identify liver injury adverse events in an administrative claims database. 
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3.9 TABLES AND FIGURES 
Table 1. Literature references and diagnosis terms for the ICD9 codes 
used in the study. 
 
Literature Reference Diagnosis Term ICD9 codes 
Jinjuvadia et al.26; Udo et al. 51 Jaundice 277.4 
Forns et al.52 Nonspecific elevation of 
transaminase or lactate 
dehydrogenase 
790.4 
Jinjuvadia et al.26; Lo Re et al. 27Udo 
et al. 51; Bui et al. 28 Forns et al.52 
Acute and subacute necrosis of 
liver 
570.x 
Jinjuvadia et al.26; Lo Re et al. 27 Udo 
et al. 51 
Liver failure, not otherwise 
specified 
572.8 





Jinjuvadia et al.26; Udo et al. 51Lo Re 
et al. 27; Bui et al. 28; Forns et al.52 
Jaundice, hepatocellular or 
Hepatitis 
573.3 
Jinjuvadia et al.26 Cholestasis 576.8 
Jinjuvadia et al.26; Bui et al. 28 Jaundice alone 782.4 
Lo Re et al. 27; Udo et al. 51Bui et al. 
28; Forns et al.52 
Acute liver failure, hepatic coma, 
hepatitis 
572.2, 572.4, 
573.8, and V42.7 
Udo et al. 51 Unspecified disorder of the liver 573.9 




Meller et al.57; Lau et al.58 Obesity V85.xx, 278 
Klompas et al.59; Hux et al.60; Wang 
et al.61 
Diabetes mellitus (type 2) 250.x0, 250.x2 
Franklin et al. 62; Wang et al.61; 
Lambert et al.23 
Hyperlipidemia 272.0-272.4 
Wang et al.61 Hypertension 401.xx-405.xx 
Du Cheyron et al.63; Moreau et al.64; 
Liu et al.55; Wang et al.61 
Renal disease 
403.xx, 404.xx, 
580.xx – 588.xx 




Issak et al.65 Alcohol abuse 305.0 
Cloutier et al.66; Lambert et al.23; Litz 
et al 67 
Schizophrenia 295.00-295.99 
Gardner et al.68; Litz et al 67 




















Table 2A. Demographic and clinical characteristics of patients 
prescribed atypical antipsychotic drugs. 
 
Demographic and clinical characteristics of patients prescribed atypical 





















Age (Years)             
Mean (SD) 49.15 (16.4) 63.72 (19.6) 63.54 (20.4) 65.9 (20.4) 
50.3 
(17.88)   
18-40 
(reference) 3577 (29.3%) 555 (14.5%) 
3964 














66-75 1123 (9.2%) 619 (16.2%) 
2410 
(13.1%) 1206 (13.3%) 89 (9.9%) 
5447 
(12.3%) 




(40.3%) 4244 (46.8%) 97 (10.8%) 
13921 
(31.3) 
Gender             
Female 


















Health plan             
HMO 









EPO 1248 (10.2%) 188 (4.9%) 942 (5.1%) 377 (4.2%) 74 (8.2%) 
2829 
(6.4%) 
IND 116 (1%) 113 (3%) 627 (3.4%) 320 (3.5%) 5 (0.5%) 
1181 
(2.7%) 
PPO 751 (6.2%) 239 (6.2%) 1321 (7.2%) 647 (7.1%) 54 (6%) 
3012 
(6.8%) 





Other 515 (4.2%) 339 (8.8%) 2002 (11%) 1130 (12.5%) 93 (10.3%) 
4092 
(9.1%) 
 HMO, Health Maintenance Organization; EPO, Exclusive Provider Organization; PPO, 
Preferred Provider Organization; POS, Point of Service; Bold values represent p-value less 
than 0.05 exposed vs. non-exposed (Statistical difference between different AAP users and 
various demographic and clinical characteristics groups on a categorical variable were 
performed using a chi-square test, and a comparison of all the continuous variables were 








Table 2B. Demographic and clinical characteristics of patients 
prescribed atypical antipsychotic drugs. 
 
Demographic and clinical characteristics of patients prescribed atypical 


















































region              
Northeast 
(reference) 1094 (9%) 267 (7%) 1545 (8.4%) 742 (8.2%) 48 (5.3%) 
3696 
(8.3%) 

































date             
Schizophreni
a/Psychosis 714 (6%)   598 (15.6%)   1768 (9.6%)   1447 (16%)   
174 
(19.3%)   
4701 






(33.6%)   765 (20%)   
3006 
(16.3%)   
1709 
(18.9%)   
344 
(38.2%)   
9930 
(22.4%)   
Anxiety 
3207 
(26.3%)   721 (18.8%)   
3607 
(19.6%)   
1611 
(17.8%)   
220 
(24.4%)   
9366 




(73.7%)   
3112 
(81.2%)   
14797 
(80.4%)   
7451 
(82.2%)   
681 
(75.5%)   
35048 
(78.9%)   
 Bold values represent p-value less than 0.05 exposed vs. non-exposed (Statistical 
difference between different AAP users and various demographic and clinical 
characteristics groups on a categorical variable were performed using a chi-square test, 













Table 2C. Demographic and clinical characteristics of patients 
prescribed atypical antipsychotic drugs. 
 
Demographic and clinical characteristics of patients prescribed atypical 





















comorbidities             
Obesity 1319 (11%)   228 (6%)   
1233 
(6.7%)   596 (6.6%)   
127 
(14.1%)   
3513 





(14.6%)   727 (19%)   
3532 
(19.2%)   
2065 
(22.8%)   
208 
(23.1%)   
8312 
(18.7%)   
Hyperlipidemia 
3987 
(32.6%)   
1407 
(36.7%)   
6891 
(37.4%)   
3569 
(39.4%)   
327 
(36.3%)   
16181 
(36.4%)   
Renal disease 498 (4.1%)   
391 
(10.2%)   
1774 
(9.6%)   1089 (12%)   53 (6%)   
3805 
(8.6%)   
Hypertension 
4449 
(36.4%)   
1882 
(49.1%)   
9205 
(50.0%)   
4850 
(53.5%)   
404 
(44.8%)   
20790 




(15.5%)   
1099 
(28.7%)   
5413 
(29.4%)   
2910 
(32.1%)   207 (23%)   
11526 
(26%)   
Alcohol abuse 475 (4%)   148 (4%)   
786 
(4.3%)   340 (4%)   60 (6.6%)   
1809 
(4.1%)   
Elixhauser 
comorbidity 
index             
0 
5676 
(46.5%)   
1799 
(46.9%)   
8493 
(46.2%)   
4143 
(45.7%)   360 (40%)   
20471 
(46.1%)   
1-3 
5795 
(47.5%)   
1666 
(43.5%)   
8098 
(44%)   
3935 
(43.4%)   
457 
(50.7%)   
19951 
(44.9%)   
4-10 743 (6.1%)   368 (9.6%)   
1813 
(9.9%)   
984 
(10.9%)   84 (9.3%)   3992 (9%)   
 Bold values represent p-value less than 0.05 exposed vs. non-exposed (Statistical 
difference between different AAP users and various demographic and clinical 
characteristics groups on a categorical variable were performed using a chi-square test, 















Table 3. Cumulative incidence of liver injury rate in patients prescribed 
atypical antipsychotic drugs. 
 






























87 (27.1%) 31 (34.1%) 
113 
(24.5%) 





70 (21.8%) 15 (16.5%) 
107 
(23.2%) 





141 (43.9%) 36 (39.6%) 
213 
(46.2%) 





12 (3.7%) 5 (5.5%) 10 (2.2%) 7 (3.6%) 3 (9.7%) 37 (3.4%) 
Acute liver 
failure 
100 (31.2%) 22 (24.2%) 
130 
(28.2%) 





























Table 4. Number of patients with or without liver injury diagnosis, 
unadjusted odds ratio, 95% confidence interval, and p-values of 

















(97.7%) 1025 (2.3%)       
AAP medications           
Aripiprazole 
11914 
(27.5%) 300 (29.3%) Reference 
0.125 
Olanzapine 3750 (8.6%) 83 (8.1%) 0.88 0.69-1.12 
Quetiapine 
17971 
(41.4%) 433 (42.4%) 0.96 0.82-1.11 
Risperidone 
8880 (20.5%) 182 (17.8%) 0.81 0.68-0.98 
Ziprasidone 874 (2%) 27 (2.6%) 1.22 0.82-1.83 
Age (Years)           




(36.6%) 508 (49.6%) 1.58 1.33-1.89 
66-75 5287 (12.2%) 160 (15.6%) 1.5 1.2-1.9 
≥76 
13736 
(31.7%) 185 (18.1%) 0.66 0.54-0.82 
Gender           
Female  
28695 




(33.9%) 371 (36.2%) 1.11 0.97-1.26 
Type of health 
plan           
HMO  
17529 
(40.4%) 357 (34.8%) Reference 
0.0005* 
EPO 2758 (6.4%) 71 (6.9%) 1.26 0.98-1.64 
IND 1159 (2.7%) 22 (2.2%) 0.93 0.6-1.44 
PPO 2916 (6.7%) 96 (9.4%) 1.62 1.29-2.03 
POS 
15041 
(34.7%) 386 (37.7%) 1.26 1.09-1.46 
Other 3986 (9.2%) 93 (9.1%) 1.15 0.9-1.44 
Type of Insurance           
Commercial 
22885 







(47.3%) 442 (43.1%) 0.85 0.75-0.96 
Geographic 
region            
Northeast 3593 (8.3%) 103 (10.1%) Reference 
<0.0001* 
Midwest 8581 (19.8%) 201 (19.6%) 0.82 0.64-1.04 
West 
12485 
(28.8%) 233 (22.7%) 0.65 0.52-0.82 
South 
18730 
(43.2%) 488 (47.6%) 0.91 0.73-1.13 
Diagnosis near 
index date (yes)           
Schizophrenia/Psy
chosis 4543 (10.5%) 158 (15.4%) 1.56 1.31-1.85 <0.0001* 
Major 
depressive/bipolar 
disorder 9611 (22.2%) 319 (31.1%) 1.59 1.39-1.82 <0.0001* 




(79.1%) 728 (71%) 0.65 0.57-0.74 <0.0001* 
Patients 
comorbidities 
(yes)           
Obesity 3362 (7.8%) 151 (14.7%) 2.06 1.73-2.45 <0.0001* 
Diabetes mellitus 
(type 2) 8037 (18.5%) 275 (26.8%) 1.61 1.4-1.86 <0.0001* 
Hyperlipidemia 
15672 
(36.1%) 509 (49.6%) 1.75 1.54-1.98 <0.0001* 
Renal disease 3692 (8.5%) 113 (11%) 1.33 1.09-1.63 0.0045* 
Hypertension 
20162 




(25.7%) 344 (33.6%) 1.46 1.28-1.66 <0.0001* 
Alcohol abuse 1728 (4%) 81 (7.9%) 2.07 1.64-2.61 <0.0001* 
Elixhauser 
comorbidity index           
0 
20133 




(44.7%) 549 (53.6%) 1.69 1.47-1.93 
4-10 3854 (8.9%) 138 (13.5%) 2.13 1.75-2.61 







Table 5. Adjusted odds ratio, 95% confidence interval, and p-values of 
independent variables for liver injury outcome using a multivariable 
logistic regression model.  
 
Multivariable logistic regression analysis of independent variables for 
liver injury outcome 
  Independent variables Odds ratio 95% CI p-value 
AAP therapy 
Olanzapine 1.05 0.82-1.35 0.7 
Quetiapine 1.16 0.99-1.36 0.06 
Risperidone 1.01 0.83-1.23 0.92 
Ziprasidone 1.13 0.76-1.69 0.55 
Gender Male 1.03 0.9-1.18 0.64 
Age 
 Age 41-65  1.15 0.95-1.39 0.14 
Age 66-75 0.92 0.72-1.18 0.52 





1.17 1.01-1.35 0.032 
Anxiety 1.19 1.03-1.37 0.022 
Comorbidity 
Obesity 1.35 1.12-1.61 0.002 
Hyperlipidemia 1.27 1.1-1.47 0.0013 
Hypertension 1.51 1.29-1.77 <0.0001 
Cardiovascular 
disease 
1.26 1.08-1.47 0.0027 




 1 to 3 1.36 1.17-1.56 <0.0001 
 4 to10 1.59 1.27-1.98 <0.0001 
Bold values indicate statistically significant (p-value less than 0.05) variables. 
Reference categories for the variable were: Elixhauser score of zero, no 
comorbidity, no diagnosis, age group 18-40, female gender, and aripiprazole AAP 
therapy.  Hosmer and Lemeshow goodness-of-fit test p-value was 0.09. ROC-AUC 















Table 6. Dose distribution of atypical antipsychotic drugs in patients 
ages 76 and older. 
 
Aripiprazole (N=1475; 5.6%); Daily 
recommended dose - 10-30 mg  
Olanzapine (N=2192; 8.4%); Daily 
recommended dose - 10-20 mg  
Doses Patients prescribed  Doses Patients prescribed  
2 mg 927 (62.9%) 2.5 mg 1349(61.5%) 
5 mg 413 (28%) 5 mg 686 (31%) 
10 mg 62 (4.2%) 7.5 mg 13 (0.6%) 
15 mg 23 (1.6%) 10 mg 130 (5.9%) 
20 mg 5 (0.34%) 15 mg 9(0.4%) 
30 mg 24 (1.63%) 20 mg 5 (0.23%) 
Risperidone (N=8574; 32.7%); Daily 
recommended dose - 2-8 mg 
Ziprasidone (N=356; 1.4%); Daily 
recommended dose - 40-80 mg twice 
Doses Patients prescribed  Doses Patients prescribed  
0.25 mg 3851 (44.9%) 20 mg 206 (57.9%) 
0.5 mg 3656 (42.6%) 40 mg 131 (36.8%) 
1 mg 854 (10%) 60 mg 4 (1.2%) 
3 mg 11 (0.13%) 80 mg 15 (4.2%) 
Quetiapine (N=13589; 51.9%); Daily 
recommended dose - 300-400 mg 
  
Doses Patients prescribed    
25 mg 11391 (84.4%)   
50 mg 1898 (14%)   
100 mg 191 (1.4%)   
150 mg 114(0.8%)   
200 mg 101 (0.74%)   
300 mg 23 (0.17%)   
Bold values indicate the highest % of 
















Table 7. Sensitivity analysis - adjusted odds ratio, 95% confidence 
interval, and p-values of independent variables for liver injury outcome 
for patients 75 and under.  
 
Multivariable logistic regression analysis of independent variables for liver 




Odds ratio 95% CI p-value 
AAP therapy 
Olanzapine 1.12 0.85-1.47 0.42 
Quetiapine 1.22 1.04-1.44 0.02 
Risperidone 1.06 0.85-1.31 0.6 
Ziprasidone 1.25 0.84-1.88 0.27 
Gender Male 1.05 0.91-1.22 0.48 
Age 
 Age 41-65  1.18 0.97-1.43 0.09 





1.16 1.0-1.35 0.05 
Anxiety 1.17 1.0-1.36 0.05 
Comorbidity 
Obesity 1.36 1.12-1.65 0.002 
Hyperlipidemia 1.31 1.11-1.54 0.0012 
Hypertension 1.46 1.23-1.73 <0.0001 
Alcohol abuse 1.63 1.27-2.08 <0.0001 
Elixhauser 
comorbidity index  
 1 to 3 1.27 1.09-1.48 0.003 
 4 to10 1.57 1.22-2.02 0.0004 
Bold values indicate statistically significant (p-value less than 0.05) variables.  Reference 
categories for the variable were: Elixhauser score of zero, no comorbidity, no diagnosis, 
age group 18-40, female gender, and aripiprazole AAP therapy.  Hosmer and Lemeshow 












Table 8. Sensitivity analysis - adjusted odds ratio, 95% confidence 
interval, and p-values of independent variables for composite liver injury 
outcome (excluding liver enzyme elevation) for patients 75 and under.  
 
Multivariable logistic regression analysis of independent variables for 
composite liver injury outcome excluding elevated enzymes for patients 
75 and younger 
  Independent variables Odds ratio 95% CI p-value 
AAP therapy 
Olanzapine 0.94 0.68-1.29 0.69 
Quetiapine 1.22 1.01-1.46 0.036 
Risperidone 1.02 0.8-1.29 0.89 
Ziprasidone 1.14 0.7-1.81 0.59 





1.26 1.06-1.48 0.007 
Comorbidity 
Obesity 1.38 1.11-1.71 0.003 
Hyperlipidemia 1.29 1.08-1.54 0.005 
Hypertension 1.57 1.31-1.89 <0.0001 
Renal disease 1.37 1.03-1.82 0.03 




1 to 3 1.32 1.1-1.71 0.002 
4 to 10 1.78 1.35-2.33 <0.0001 
Bold values indicate statistically significant (p-value less than 0.05) variables.  Reference 
categories for the variable were: Elixhauser score of zero, no comorbidity, no diagnosis, 
age group 18-40, female gender, and aripiprazole AAP therapy.  Hosmer and Lemeshow 













Table 9. Sensitivity analysis - adjusted odds ratio, 95% confidence 
interval, and p-values of independent variables for severe liver injury 
outcome including liver necrosis and acute liver failure for patients 75 
and under.  
 
 
Multivariable logistic regression analysis of independent variables for 
severe liver injury outcome including liver necrosis and acute liver 
failure for patients 75 and younger 
  Independent variables Odds ratio 95% CI p-value 
AAP therapy 
Olanzapine 0.87 0.52-1.45 0.58 
Quetiapine 1.06 0.78-1.43 0.71 
Risperidone 0.77 0.51-1.16 0.21 
Ziprasidone 1.48 0.76-2.87 0.24 
Gender Male 0.92 0.71-1.2 0.54 
Insurance Medicare 1.53 1.1-2.1 0.01 
Region 
Midwest 0.56 0.36-0.86 0.008 
West 0.52 0.33-0.81 0.004 




1.39 1.06-1.8 0.017 
Comorbidity 
Hyperlipidemia 1.41 1.06-1.87 0.017 
Renal disease 1.68 1.08-2.6 0.02 
Cardiovascular disease 1.39 1.02-1.89 0.04 
Bold values indicate statistically significant (p-value less than 0.05) variables.  
Reference categories for the variable were:  no comorbidity, no diagnosis, commercial 
insurance, northeast region, female gender, and aripiprazole AAP therapy.  Hosmer 











































































Figure 3.  Adjusted odds of liver injury associated with AAP use and 
other risk factors  
 
0.0 0.5 1.0 1.5 2.0 2.5
Elixhauser score - 4-10
*Elixhauser score - 1-3
Comorbidity - Alcohol abuse (yes)
Comorbidity - Cardiovascular disease (yes)
Comorbidity - Hypertension (yes)
Comorbidity - Hyperlipidemia (yes)
Comorbidity - Obesity (yes)
Diagnosis - Anxiety (yes)
Diagnosis - depressive/bipolar disorder (yes)




*AAP therapy - Ziprasidone
*AAP therapy - Risperidone
*AAP therapy - Quetiapine




*P-value was greater than 0.05.  Reference categories for the variable were: AAPs 
were compared with aripiprazole as reference group; Elixhauser score of zero, no 
comorbidity, no diagnosis, age group 18-40, female gender, and aripiprazole AAP 
therapy.  Hosmer and Lemeshow goodness-of-fit test p-value was 0.09. ROC-AUC 
value was 0.66. 
